0001140361-22-042317.txt : 20221118 0001140361-22-042317.hdr.sgml : 20221118 20221118161711 ACCESSION NUMBER: 0001140361-22-042317 CONFORMED SUBMISSION TYPE: 6-K/A PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221118 DATE AS OF CHANGE: 20221118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunocore Holdings plc CENTRAL INDEX KEY: 0001671927 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39992 FILM NUMBER: 221402151 BUSINESS ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY BUSINESS PHONE: 01235 5430281 MAIL ADDRESS: STREET 1: 90 PARK DRIVE STREET 2: MILTON PARK, ABINGDON CITY: OXFORDSHIRE STATE: X0 ZIP: OX14 4RY FORMER COMPANY: FORMER CONFORMED NAME: Immunocore Ltd DATE OF NAME CHANGE: 20160412 6-K/A 1 brhc100441106ka.htm 6-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

Amendment No. 1

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2022

Commission File Number: 001-39992

Immunocore Holdings plc

(Translation of registrant’s name into English)

92 Park Drive

Milton Park

Abingdon, Oxfordshire OX14 4RY

United Kingdom

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

This Report on Form 6-K/A (this “Amendment”) amends the Report on Form 6-K filed by Immunocore Holdings plc (the “Company”) on November 9, 2022 (the “Original 6-K”) solely to provide the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2022 formatted in Inline eXtensible Business Reporting Language (“ixBRL”) in accordance with Rule 405 of Regulation S-T and paragraph C.(6)(a)(ii) of the General Instructions to Form 6-K, attached hereto as Exhibit 99.1. Such Unaudited Condensed Consolidated Interim Financial Statements were previously filed without iXBRL as Exhibit 99.1 to the Original 6-K. Exhibit 101 provides the financial statements and related notes from the Report formatted in iXBRL.

Except as described above, this Amendment speaks as of the original filing date of the Original 6-K and does not amend, update or restate any information set forth in the Original 6-K or reflect any events that occurred subsequent to the original filing date of the Original 6-K.

INCORPORATION BY REFERENCE

This Amendment, including the Exhibits hereto, shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File Nos. 333-255182 and 333-265000) and the registration statement on Form F-3ASR (File No. 333-264105) of the Company and to be a part thereof from the date on which this Amendment is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBITS

Exhibit No.		Description
99.1		Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2022.

101		The following materials from this Report are formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Unaudited Condensed Consolidated Statements of Profit/Loss and Other Comprehensive Loss for the Three and Nine Months Ended September 30, 2022 and 2021; (ii) Unaudited Condensed Consolidated Statements of Financial Position as at September 30, 2022 and December 31, 2021; (iii) Unaudited Condensed Consolidated Statements of Changes in Equity for the Nine Months Ended September 30, 2022 and 2021; (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021; and (v) Notes to the Unaudited Condensed Consolidated Interim Financial Statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		IMMUNOCORE HOLDINGS PLC

Date:	November 18, 2022	By:	/s/ Bahija Jallal, Ph.D.
			Name	Bahija Jallal, Ph.D.
			Title:	Chief Executive Officer

EX-99.1 2 brhc10044110_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

		Page

Unaudited Condensed Consolidated Statements of Profit / Loss and Other Comprehensive Loss for the Three and Nine Months Ended September 30, 2022 and 2021		2
Unaudited Condensed Consolidated Statements of Financial Position as at September 30, 2022 and December 31, 2021		3
Unaudited Condensed Consolidated Statements of Changes in Equity for the Nine Months Ended September 30, 2022 and 2021		4
Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021		5
Unaudited Condensed Consolidated Notes to the Financial Statements		6

Immunocore Holdings plc

Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Profit / (Loss) and Other Comprehensive Loss

			Three months ended September 30,						Nine Months Ended September 30,
	Notes		2022 £’000			2021 £’000			2022 £’000			2021 £’000
Product revenue, net		3		33,252			—			64,926			—
Pre-product revenue, net		3		3,051			474			9,588			474
Total revenue from sale of therapies				36,303			474			74,514			474
Collaboration revenue		3		4,896			5,450			21,161			19,453
Total revenue				41,199			5,924			95,675			19,927

Cost of product revenue		2		(63	)		—			(345	)		—
Research and development costs				(23,301	)		(16,798	)		(62,032	)		(53,154	)
Selling and administrative expenses		4		(11,663	)		(20,048	)		(50,580	)		(64,033	)
Net other operating (expense) / income				—			(28	)		1			(70	)
Operating profit / (loss)				6,172			(30,950	)		(17,281	)		(97,330	)

Finance income				597			8			725			42
Finance costs		5		(1,785	)		(1,317	)		(4,515	)		(4,465	)
Non-operating expense				(1,188	)		(1,309	)		(3,790	)		(4,423	)

Profit / (loss) before taxation				4,984			(32,259	)		(21,071	)		(101,753	)
Income tax credit		6		1,244			2,125			5,050			9,619
Profit / (loss) for the period				6,228			(30,134	)		(16,021	)		(92,134	)

Other comprehensive loss
Other comprehensive loss that is or may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign operations				(1,730	)		(38	)		(1,848	)		(92	)
Total Other comprehensive loss for the period				(1,730	)		(38	)		(1,848	)		(92	)

Total comprehensive income / (loss) for the period				4,498			(30,172	)		(17,869	)		(92,226	)
Basic earnings / (loss) per share - £		7		0.13			(0.69	)		(0.36	)		(2.19	)
Diluted earnings / (loss) per share - £		7		0.12			(0.69	)		(0.36	)		(2.19	)

The accompanying notes form part of these unaudited condensed consolidated interim financial statements.

Immunocore Holdings plc

Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Financial Position as at

	Notes		September 30, 2022 £’000			December 31, 2021 £’000
Non-current assets
Property, plant and equipment				6,580			8,944
Right of use assets		9		23,963			22,593
Other non-current assets				6,749			4,935
Deferred tax asset		6		3,860			2,575
Total non-current assets				41,152			39,047
Current assets
Inventory		2		854			—
Trade and other receivables		8		40,968			15,208
Tax receivable				14,510			9,632
Cash and cash equivalents				347,189			237,886
Total current assets				403,521			262,726
Total assets				444,673			301,773
Equity
Share capital				96			88
Share premium				120,147			212,238
Foreign currency translation reserve				(1,759	)		89
Other reserves				337,847			386,167
Share-based payment reserve				74,538			54,357
Accumulated deficit				(236,050	)		(481,392	)
Total equity				294,819			171,547
Non-current liabilities
Interest-bearing loans and borrowings				45,563			37,226
Deferred revenue		3		—			6,408
Lease liabilities		9		26,965			25,355
Provisions				108			57
Total non-current liabilities				72,636			69,046
Current liabilities
Trade and other payables		12		64,928			35,436
Deferred revenue		3		10,681			24,450
Lease liabilities		9		1,553			1,255
Provisions				56			39
Total current liabilities				77,218			61,180
Total liabilities				149,854			130,226
Total equity and liabilities				444,673			301,773

The accompanying notes form part of these unaudited condensed consolidated interim financial statements.

Immunocore Holdings plc

Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Changes in Equity

	Notes		Share capital £’000		Share premium £’000			Foreign currency translation reserve £’000			Share- based payment reserve £’000		Other reserve £’000			Accumulated deficit £’000			Total equity £’000
At January 1, 2022				88		212,238			89			54,357		386,167			(481,392	)		171,547
Loss for the period				—		—			—			—		—			(16,021	)		(16,021	)
Other comprehensive loss				—		—			(1,848	)		—		—			—			(1,848	)
Total comprehensive loss for the period				—		—			(1,848	)		—		—			(16,021	)		(17,869	)
Exercise of share options				1		4,535			—			—		—			—			4,536
Capital reduction in Group’s parent company		10		—		(213,043	)		—			—		(48,320	)		261,363			—
Issue of share capital		10		7		116,417			—			—		—			—			116,424
Equity-settled share-based payment transactions		11		—		—			—			20,181		—			—			20,181
At September 30, 2022				96		120,147			(1,759	)		74,538		337,847			(236,050	)		294,819

	Notes		Share capital £’000		Share premium £’000		Foreign currency translation reserve £’000			Share- based payment reserve £’000		Other reserve £’000		Accumulated deficit £’000			Total equity £’000
At January 1, 2021				64		—		163			18,821		386,167		(349,869	)		55,346
Loss for the period				—		—		—			—		—		(92,134	)		(92,134	)
Other comprehensive loss				—		—		(92	)		—		—		—			(92	)
Total comprehensive loss for the period				—		—		(92	)		—		—		(92,134	)		(92,226	)
Issue of share capital				24		210,961		—			—		—		—			210,985
Exercise of share options				—		644		—			—		—		—			644
Equity-settled share-based payment transactions		11		—		325		—			26,813		—		—			27,138
At September 30, 2021				88		211,930		71			45,634		386,167		(442,003	)		201,887

The accompanying notes form part of these unaudited condensed consolidated interim financial statements.

Immunocore Holdings plc

Unaudited Condensed Consolidated Interim Financial Statements

Unaudited Condensed Consolidated Statements of Cash Flows

			Nine Months Ended September 30,
	Notes		2022 £’000			2021 £’000
Cash flows from operating activities
Loss for the period				(16,021	)		(92,134	)
Adjustments for:
Equity settled share-based payment expense		11		20,181			27,138
Depreciation				4,794			5,294
Net finance costs (non-operating expense)				3,790			4,423
Foreign exchange differences				(20,498	)		320
Other				(1	)		273
Income tax credit		6		(5,050	)		(9,619	)
Working capital adjustments:
Increase in receivables and other non-current assets				(25,021	)		(1,684	)
Increase in trade and other payables				27,501			3,085
Decrease in deferred revenue				(20,177	)		(16,853	)
Other working capital movements				(807	)		(21	)
Cash used in operations				(31,309	)		(79,778	)
Net taxation paid				(614	)		—
Net cash used in operating activities				(31,923	)		(79,778	)
Cash flows used in investing activities
Proceeds from sale of property, plant and equipment				5			64
Purchase of property, plant and equipment				(869	)		(730	)
Proceeds from investment in sub-leases				—			549
Other investing activities				725			15
Net cash flows used in investing activities				(139	)		(102	)
Cash flows from financing activities
Gross proceeds from issue of share capital		10		116,812			226,528
Costs from issue of share capital		10		(388	)		(15,543	)
Exercise of share options				4,536			644
Interest paid on non-current interest-bearing loan				(3,050	)		(2,473	)
Repayment of lease liabilities				(2,265	)		(2,465	)
Net cash flows from financing activities				115,645			206,691
Increase in cash and cash equivalents				83,583			126,811
Net foreign exchange difference on cash				25,720			24
Cash and cash equivalents at beginning of the year				237,886			129,716
Cash and cash equivalents at end of the period				347,189			256,551

The accompanying notes form part of these unaudited condensed consolidated interim financial statements.

Immunocore Holdings plc

Unaudited Condensed Consolidated Interim Financial Statements

Notes to the Financial Statements

1. Organization and nature of business

General information

Immunocore Holdings plc (the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries: Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited (collectively referred to as the “Group”).

The Company’s American Depositary Shares (“ADSs”) began trading on the Nasdaq Global Select Market under the ticker symbol “IMCR” on February 5, 2021, following its initial public offering (“IPO”). The IPO and concurrent private placement generated net proceeds of £210,985,000 after underwriting discounts, commissions and directly attributable offering expenses. In July 2022, the Company issued and sold a total of 3,733,333 ordinary shares to certain institutional accredited investors as a private investment in public entity (the “PIPE”) pursuant to a securities purchase agreement, generating proceeds of £116,812,000 ($140,000,000) before deductions for offering expenses of £388,000.

The principal activity of the Group is pioneering the development and sale of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, the Group is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.

In January and April 2022, the Group received approval from the U.S. Food and Drug Administration (“FDA”) and European Commission (“EC”), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma (“mUM”). In June 2022, the UK’s MHRA, Health Canada, and the Australian Government Department of Health’s TGA have each approved KIMMTRAK for the treatment of HLA-A*02:01-positive adult patients with unresectable or mUM. KIMMTRAK is now approved in over 30 countries with commercial launches underway in the U.S., Germany, France and Canada. The Group expects to obtain regulatory approval for KIMMTRAK in further territories in the next year.

2. Significant accounting policies

Basis of preparation

The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with International Accounting Standard 34, “Interim Financial Reporting” (“IAS 34”). Except as described in Significant Accounting Policies below, the accounting policies applied in these interim financial statements are the same as those applied in the Group’s consolidated financial statements as at and for the year ended December 31, 2021.

The unaudited condensed consolidated interim financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Group for the year ended December 31, 2021 included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 3, 2022 (the “Annual Report”). New accounting policies applicable to the three and nine months ended September 30, 2022, are outlined further below.

The unaudited condensed and consolidated interim financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in pounds sterling which is the Company’s functional currency. All values are rounded to the nearest thousand, except where otherwise indicated.

Date of authorization

These unaudited condensed consolidated interim financial statements were prepared at the request of the Company’s Board of Directors (the “Board”) and were approved by the Board on November 9, 2022, and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer of the Group.

Adoption of new accounting standards

There have been no new accounting standards adopted by the Group in 2022 which have had a material impact on these unaudited condensed consolidated interim financial statements. There are no standards issued but not yet effective that the Group expects to have a material impact on its financial statements.

Going concern

The Group reported cash and cash equivalents of £347,189,000 and net current assets of £326,303,000 as at September 30, 2022, with an operating profit / (loss) for the three and nine months ended September 30, 2022 of £6,172,000 and (£17,281,000), respectively, and net cash used in operating activities for the nine months ended September 30, 2022 of £31,923,000. The negative operational cash flow was largely due to the Group’s continued focus on research, development, and clinical activities to advance preclinical and clinical programs within the Group’s pipeline. The Group generated net product and net pre-product revenue totalling £36,303,000 and £74,514,000 during the three and nine months ended September 30, 2022, respectively. In July 2022, the Group received £116,812,000 ($140,000,000) before deduction of attributable expenses of £388,000 following the PIPE.

In assessing the going concern assumptions, the Board has undertaken an assessment of the current business and strategy forecasts covering a two-year period, which includes anticipated KIMMTRAK revenue. In assessing the downside risks, the Board has also considered scenarios incorporating a range of revenue arising from KIMMTRAK sales. As part of considering the downside risks, the Board has considered the impact of the ongoing coronavirus 2019 (‘‘COVID-19’’) pandemic and other potential economic impacts including the war in Ukraine and related geopolitical tensions, as well as global inflation, capital market instability, exchange rate fluctuations, and increases in commodity, energy and fuel prices. The Board has concluded that while these may have a future impact on the Group’s business and implementation of its strategy and plans, it anticipates that any such impact will be minimal on clinical trials or other business activities over the period assessed for going concern purposes. As of the date of these financial statements, the Group is not aware of any specific event or circumstance that would require the Group to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Group’s financial statements.

Given the current cash position and the assessment performed, the Board believes that the Group will have sufficient funds to continue to meet its liabilities as they fall due throughout the forecast period outlined above and therefore, the Group has prepared the financial statements on a going concern basis. This scenario is based on the Group’s lower range of anticipated revenue levels. As the Group continues to incur significant expenses in the pursuit of its business strategy, including further commercialization and marketing plans for KIMMTRAK, additional funding will be needed before further existing clinical and preclinical programs may be expected to reach commercialization, which would potentially lead to additional operational cash inflows. Until the Group can generate revenue from product sales sufficient to fund its ongoing operations and further develop its pipeline, if ever, it expects to finance its operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements.

Estimates and judgements

The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as contingent liabilities and income and expenses in the financial period. The estimates and associated assumptions are based on information available when the unaudited condensed consolidated interim financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to market changes or circumstances arising that are beyond the Group’s control. Therefore, estimates may vary from eventual outcomes and may be subject to updates in future reported periods.

Judgements and estimates made, together with our significant accounting policies, are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2021, and are presented in the Group’s Annual Report. Significant updates to the Group’s estimates and accounting policies for the three and nine months ended September 30, 2022 are outlined below.

Critical Accounting Estimates

Estimated rebates, chargebacks and product returns

As outlined below in the “Product revenue, net” policy, the Group recognizes revenue net of estimated deductions for rebates, chargebacks, other customer fees and product returns.

Due to its limited history of product sales in the United States having only recently received regulatory approval for its first product, the Group has limited directly comparable information of actual rebate claims, chargebacks or levels of product returns, and the Group’s early sales information may have limited predictive value. The Group uses the expected value method to estimate revenue deductions, which considers the likelihood of a rebate, chargeback or product return being applicable to sales. The proportion of sales subject to a rebate or chargeback, and the level of product returns, is inherently uncertain and the Group’s estimates are based on internal assumptions, which may change as the Group develops more product experience, and third-party data, which the Group assesses for reliability and relevance.

Rebates and chargebacks

The Group is subject to state government Medicaid programs and other qualifying federal and state programs in the United States requiring rebates to be paid to participating state and local government entities, depending on the eligibility and circumstances of patients treated with KIMMTRAK after the Group has sold vials to specialty distributors. The Group is also subject to chargebacks from its specialty distributors under the 340B program in the United States, whereby qualifying hospitals are entitled to purchase KIMMTRAK at a lower price. For such sales, the Group’s specialty distributors charge back the difference between the wholesale acquisition cost and this lower price. Estimating rebate and chargeback deductions from revenue is judgmental due to the time delay between the date of the sale to specialty distributors and the subsequent dates on which the Group is able to determine actual amounts of chargebacks and rebates. The Group forms estimates of 340B chargeback deductions by analyzing sell-through data relating to the hospital mix of onward sales made by specialty distributors. For Medicaid and other rebates, the Group forms estimates based on internal forecasts of the patient mix and external health coverage statistics. Judgment is applied to consider the relevance and reliability of information used to make these estimates.

Judgment is also required in determining the amount of the Group’s net pre-product revenue and product revenue in France. Rebates payable to the Economic Committee for Health Products (“CEPS”) under compassionate use, early access and commercial programs are subject to a high degree of estimation uncertainty. The Group’s estimate of these rebates represents the difference between the expected agreed price for the commercial sale of KIMMTRAK in France, which is subject to price negotiation, and the initial price of tebentafusp and KIMMTRAK sold under early access and commercial programs until this price is agreed. Analysis of further legislative requirements, sales volumes and the expected benefit of KIMMTRAK to patients in France is also required in the assessment of rebates payable. The Group applies judgement to assess internal targets, pricing information of other therapies approved for sale in France, information obtained from price negotiations of KIMMTRAK in other countries, and information connected with KIMMTRAK’s safety profile when forming its estimated rebate deduction from revenue.

Product returns

The Group considers several inputs when estimating potential levels of product returns. Due to the nature of KIMMTRAK as a therapy, the Group expects no product returns following patient administration by trained healthcare professionals. The Group applies judgement in assessing the level of returns for sales made to distributors which have yet to be administered to patients. The Group considers industry average return levels, distributor sell-through rates, the levels of inventory in the distribution channel, the period of time for which inventory has been held by its distributors, the level of orders placed, the expiry date of products sold, and its distributors’ right to return products in the case of vials of KIMMTRAK with a shorter period to expiry. As orders are typically placed based on scheduled administration by hospitals and healthcare facilities, the Group does not expect a significant level of product returns.

Significant Accounting Policies

Product revenue, net

Product revenue, net, relates to the sale of KIMMTRAK following marketing approval. The Group recognizes revenue at the point in time that control transfers to a customer, which is typically on delivery. The Group also operates under consignment arrangements where control passes when the Group’s distributor takes KIMMTRAK out of consignment inventory. The amount of revenue recognized under its arrangements reflects the consideration to which the Group expects to be entitled to, net of estimated deductions for rebates, chargebacks, other customer fees and product returns. Estimated revenue deductions are updated at the end of each reporting period using the latest available data. The Group considers whether any part of amounts expected to be received should be constrained to ensure that it is highly probable that a significant reversal in the cumulative revenue recognized will not occur. Estimating such deductions involves judgments which are detailed further above under “Critical accounting estimates”.

The Group’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list prices with standard payment terms typically between one and two months. When the Group has the right to offset chargebacks against trade receivables and the parties have agreed to settle the payments net, chargebacks are recorded as a reduction in trade receivables. Other chargebacks, rebates and deductions are recognized as an accrual in the condensed consolidated statement of financial position.

The Group’s customers are hospitals and healthcare providers in certain countries, where KIMMTRAK is sold through an agent acting on the Group’s behalf.

Pre-product revenue, net

Pre-product revenue, net, relates to the sale of tebentafusp under a compassionate use and an early access program in France up to September 2022. These programs provided patients with access to tebentafusp before KIMMTRAK became available as a marketed product in France. Pre-product revenue is recognized on delivery of tebentafusp to healthcare providers, which is the point in time when control is transferred. Such revenue is recognized net and represents the prices set by the Group that are expected to be retained after estimated deductions and to the extent that it is highly probable that a significant reversal of revenue will not occur. These variable estimated deductions include both an estimate of government rebates payable and an estimate of returns in the case of expiry, damage or other instances. The total rebate payable by the Group is dependent on the outcome of price negotiations with the French government, and the Group makes an estimate of these amounts payable each reporting period based on available pricing information and the applicable regulations. Returns are estimated based on industry trends and information provided by the Group’s distributors.

The estimates for rebates and returns deducted from pre-product revenue are recorded in the period the related pre-product revenue is recognized and are classified under Accruals within Trade and other payables in the Condensed Consolidated Statement of Financial Position. Costs of pre-product revenue are expensed when incurred and include costs associated with previous manufacturing of tebentafusp and other third-party selling expenses. Previous manufacturing costs were recognized in Research and development expenses at the time, and third-party selling expenses are recognized within Selling and administrative expenses.

Cost of product revenue

Cost of product revenue represents production costs including raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale. Due to the Group’s manufacturing arrangements, overheads and internal costs of product revenue are minimal. Further information on Cost of product revenue is included within the ‘Inventories’ policy below.

Trade Receivables

Trade receivables include amounts invoiced or contractually accrued where only the passage of time is required before payment is received under the Group’s collaboration agreements and other revenue arrangements. Trade receivables are assessed for impairment using the simplified approach under IFRS 9, Financial Instruments, which requires lifetime expected losses to be recognized with the initial recognition of the receivable. Due to its lack of sales history, the Group estimates expected credit losses using internal information, industry credit default information, and comparable information available from companies with similar customers. As of September 30, 2022, the amount of expected credit losses is not material.

Inventories

Inventories include finished goods manufactured for commercial sale, items in the process of being manufactured for commercial sale, and the materials to be used in the manufacturing process. The principal costs in manufacturing the Group’s inventories are raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale.

Inventories are measured at weighted average cost and presented as assets in the Condensed Consolidated Statement of Financial Position to the extent that they are recoverable. Inventories are stated at the lower of cost and net realizable value, and the Group assesses whether an expense should be recognized to write down inventory values at each reporting period. Where this expense relates to inventories manufactured or developed following marketing approval of KIMMTRAK, the Group recognizes the expense within Cost of product revenue. Prior to receiving marketing approval, the Group recorded the expense for prelaunch inventory expected to be sold in the ordinary course of business within Research and development expenses. Reversals of previous write-downs of inventories are recognized within Cost of product revenue or Research and development expenses, depending on where the write-down was originally recognized.

As at September 30, 2022, the Group held a provision against the value of its inventories of £701,000, of which £185,000 has been recognized in Cost of product revenue in the Condensed Consolidated Statement of Profit / (Loss) and Comprehensive Loss in the nine months ended September 30, 2022.

Due to the low costs involved in manufacturing KIMMTRAK, inventory costs and Cost of product revenue are not material at this time, and the Group does not expect these costs to be material for the foreseeable future.

3. Revenue

Revenue recognized during the three and nine months ended September 30, 2022 and 2021 consisted of Product revenue, net, from the sale of KIMMTRAK, Pre-product revenue, net, from the sale of tebentafusp under compassionate use and early access programs, and revenue from collaboration agreements.

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000

Product revenue, net		33,252		—		64,926		—
Pre-product revenue, net		3,051		474		9,588		474
Total revenue from sale of therapies		36,303		474		74,514		474
Collaboration revenue
GSK		—		1,263		—		5,919
Eli Lilly		—		—		7,361		—
Genentech		4,896		4,187		13,800		13,534
Total collaboration revenue		4,896		5,450		21,161		19,453
Total revenue		41,199		5,924		95,675		19,927

Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program are presented by region based on the location of the customer below.

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000
United States		22,508		—		48,327		—
Europe		13,034		474		25,423		474
Rest of World		761		—		764		—
Total revenue from sale of therapies		36,303		474		74,514		474

Product revenue, net

During the three and nine months ended September 30, 2022, the Group recognized £33,252,000 and £64,926,000 of net product revenue, respectively, relating to the sale of KIMMTRAK primarily in the United States and Europe after estimated deductions for rebates, chargebacks, other customer fees and returns which are recognized in accruals as set out in the Group’s accounting policies.

Pre-product revenue, net

During the three and nine months ended September 30, 2022, the Group recognized £3,051,000 and £9,588,000 of net pre-product revenue, respectively, relating to the sale of tebentafusp under a compassionate use and early access program in France after estimated deductions for rebates and returns which are recognized in accruals as set out in the Group’s accounting policies (for both the three and nine months ended September 30, 2021: £474,000 of Pre-product revenue, net was recorded). In September 2022, the Group began selling KIMMTRAK as a commercial product in France, and these sales are reflected in Product revenue, net.

Genentech Collaboration

During the three and nine months ended September 30, 2022, the Group recognized £4,896,000 and £13,800,000 of revenue, respectively, relating to the 2018 Genentech Agreement and IMC-C103C (for the three and nine months ended September 30, 2021: £4,187,000 and £13,534,000, respectively). The revenue recognized represents both deductions from deferred revenue and research and development costs reimbursed, predominantly for clinical trial costs. Such reimbursements arise in order to ensure that research and development costs are shared equally under the 2018 Genentech Agreement. Of the revenue recognized during the three and nine months ended September 30, 2022, £624,000 and £984,000 of revenue represents research and development costs reimbursements. For the three and nine months ended September 30, 2021, the Group recognized research and development cost reimbursements of £87,000 and £717,000 respectively.

GSK Collaboration

GSK and the Group elected not to progress the final program under the GSK Agreement in 2021, and there is no further revenue to recognize following notice of termination in 2021 and final termination of the GSK Agreement in the three months ended March 31, 2022. Accordingly, during the three and nine months ended September 30, 2022, the Group recognized no revenue relating to the GSK Agreement (for the three and nine months ended September 30, 2021: £1,263,000 and £5,919,000, respectively).

Eli Lilly Collaboration

During the three and nine months ended September 30, 2022, the Group recognized £nil and £7,361,000, respectively, relating to the Eli Lilly Agreement (for the three and nine months ended September 30, 2021: £nil).

The Group released the remaining deferred revenue attributed to the third target under the collaboration after the parties agreed to terminate the agreement during the three months ended March 31, 2022. No further revenue under the Eli Lilly Collaboration is expected.

Deferred revenue

Of the total revenue recognized during the three and nine months ended September 30, 2022, £4,272,000 and £20,177,000, respectively, was included in deferred revenue at January 1, 2022. No revenue was recognized in the three and nine months ended September 30, 2022 relating to performance obligations satisfied in previous years (for the three and nine months ended September 30, 2021: £nil). The remaining deferred revenue as at September 30, 2022 in the condensed consolidated statement of financial position relates to the 2018 Genentech agreement. The Group expects to recognize this remaining revenue within a year.

4. Selling and administrative expenses

There were £15,184,000 and £24,343,000, respectively, of foreign exchange gains, which the Group classifies within Selling and administrative expenses, for the three and nine months ended September 30, 2022, compared to gains of £3,338,000 and £1,080,000 in the three and nine months ended September 30, 2021. These gains arise on a number of foreign currency items, and the translation of monetary foreign currency balances in the Group’s main operating subsidiary in the United Kingdom has been significantly impacted by changes in exchange rates between pounds sterling and U.S. dollars in the three months ended September 30, 2022. The Group periodically assesses its exposure to foreign currency fluctuations and, to the extent practical, seeks to minimize foreign currency risk by maintaining cash and cash equivalents of each currency at levels sufficient to meet foreseeable expenditure. The Group has not to date entered into hedging instruments to reduce the impact of foreign currency fluctuations, but it may do so in the future.

5. Finance costs

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000
Interest expense on lease liabilities		461		428		1,316		1,301
Interest expense on financial liabilities measured at amortized cost		1,324		889		3,199		3,164
		1,785		1,317		4,515		4,465

Interest expense on financial liabilities measured at amortized cost for the three and nine months ended September 30, 2022 and 2021 is related to the $50.0 million of borrowings under the Group’s debt facility with Oxford Finance. The expense for the nine months ended September 30, 2021, includes £546,000, representing a fee of $750,000, that became payable to Oxford Finance upon the completion of the IPO. The interest expense on the Group’s borrowings with Oxford Finance increased in the three months ended September 30, 2022, following an increase in the floating interest incurred on the loan. To reduce exposure to rising interest rates, the Group entered into a loan agreement on November 8, 2022, with investment funds managed by Pharmakon Advisors, LP (the “Pharmakon Loan Agreement”), providing for term loans to the Group in an aggregate principal amount of up to $100 million to be funded in two tranches. The first tranche, in the amount of $50 million, bears a fixed rate of interest of 9.75% and will mature in 6 years of draw. The proceeds from the first tranche, together with cash on hand, were used to repay the Group’s existing loan in the condensed consolidated statement of financial position of £45,563,000. This value at September 30, 2022 included a repayment fee of £1,579,000 (and excluded an early repayment fee of £225,000, which became payable when the Group elected to repay the Oxford loan).

6. Income tax

An income tax credit is recognized at an amount determined by multiplying the loss before taxation for the interim reporting period by the Group’s best estimate of the estimated annual income tax credit rate expected for the full financial year, adjusted for the tax effect of certain items recognized in full in the interim period. As such, the effective tax credit rate in the interim financial statements may differ from the Group’s estimate of the effective tax credit rate for the annual financial statements.

The Group’s consolidated estimated effective tax credit rate for the nine months ended September 30, 2022 was 24.0% (for the nine months ended September 30, 2021: 9.5%). During the nine months ended September 30, 2022, the Company recorded a tax credit of £5,050,000 related to its research and development tax credits in the United Kingdom and the income tax obligations of its operating companies in the U.S. and the Republic of Ireland, which generate profit for tax purposes.

A deferred tax asset of £3,860,000 has been recognized as of September 30, 2022 (December 31, 2021: £2,575,000) representing unused tax credits and capitalized research and development costs carried forward for one of the Group’s subsidiaries, Immunocore LLC, following a periodic assessment of all available and applicable information, including its forecasts of costs and future profitability and the resulting ability to utilise the recognized deferred tax assets over a short period of time.

7. Basic and diluted profit / (loss) per share

	For the three months ended September 30,					For the nine months ended September 30,
	2022		2021			2022			2021
Profit / (loss) for the period (£’000s)		6,228		(30,134	)		(16,021	)		(92,134	)
Basic weighted average number of shares		46,998,420		43,796,084			44,944,827			42,030,746
Adjustment for stock options with dilutive effect		4,444,856		—			—			—
Diluted weighted average number of shares		51,443,276		43,796,084			44,944,827			42,030,746
Basic earnings / (loss) per share (£) (1)		0.13		(0.69	)		(0.36	)		(2.19	)
Diluted earnings / (loss) per share (£) (1)		0.12		(0.69	)		(0.36	)		(2.19	)

(1) Basic profit / (loss) per share is calculated by dividing the profit or loss for the period attributable to the equity holders of the Group by the weighted average number of ordinary shares outstanding during the period, including ordinary shares represented by ADSs. Except for the three months ended September 30, 2022, the dilutive effect of potential shares through equity settled transactions is considered to be anti-dilutive as they would decrease the loss per share and are, therefore, excluded from the calculation of diluted loss per share. For the three months ended September 30, 2022, there were 88,695 of the potential ordinary shares granted under the Group’s option plans excluded from the calculation for diluted options per share, because they are considered to be anti-dilutive.

8. Trade and other receivables

	September 30, 2022 £’000		December 31, 2021 £’000
Trade receivables		25,809		6,047
Other receivables		6,214		1,470
Prepayments and accrued income		8,945		7,691
		40,968		15,208

Included within prepayments and accrued income are amounts paid in advance for clinical trials that are expected to be expensed within 12 months.

9. Leases

On July 13, 2022, the Group entered into a new lease for additional laboratory space in the United Kingdom. The lease expires in 2042; however, it is freely terminable at the Group’s option at three points during the lease prior to the expiration date. The Group may be required to make total payments of up to £5,483,000 under the lease agreement. The lease was previously disclosed as a contingent liability of £1,122,000 as at December 31, 2021, which represented the minimum amount of mandatory payments if the Group became required to enter into the lease.

In the three months ended September 30, 2022, the Group recognized an initial right-of-use asset and lease liability of £2,472,000 in the Condensed Consolidated Statement of Financial Position in relation to this lease.

10. Capital and reserves

In April 2022, the Company completed a reduction of its share capital, as contemplated in the registration statement for the Company’s initial public offering, whereby (i) the whole of the amount standing to the credit of the Company’s share premium account was cancelled and (ii) 23,702,856,974 ordinary shares and 457,338,326 non-voting ordinary shares (which were issued by way of a bonus issue on April 25, 2022 for the purpose of capitalising the Company’s merger reserve) were cancelled. The distributable reserves created by the reduction of capital amounted to £261.4 million.

In July 2022, the Company issued and sold 2,000,000 ADSs of nominal value £0.002 each and 1,733,333 non-voting ordinary shares of nominal value £0.002 each (the “PIPE Securities”), to certain institutional accredited investors (the “Investors”) at a purchase price of $37.50 per ordinary share as a private investment in public equity (“PIPE”) pursuant to a securities purchase agreement with such Investors dated July 15, 2022, generating gross proceeds of £116,812,000 ($140,000,000) before deducting offering expenses payable by the Company of £388,000.

The Condensed Consolidated Statement of Changes in Equity shows the impact of the capital reduction and the PIPE. The table below shows the movement in the number of issued shares during the nine months ended September 30, 2022.

	Ordinary Shares		Deferred Shares
At January 1, 2022		43,862,850		5,793,501
New shares issued for cash		3,733,333		—
Exercise of share options		308,776		—
At September 30, 2022		47,904,959		5,793,501

11. Share-based payments

During the three and nine months ended September 30, 2022 the total share-based payment charge was £6,093,000 and £20,181,000 respectively (for the three and nine months ended September 30, 2021, £9,200,000 and £27,138,000, respectively).

The Company granted 2,100 and 4,000 options in the three months ended September 30, 2022, and 2021, respectively, and 1,365,753 and 4,538,527 options in the nine months ended September 30, 2022, and 2021, respectively. The options in both periods were valued using the Black-Scholes model, with the majority vesting over a four-year period from the date of grant, and with 25% of the award vesting at the end of the first year and the remaining award vesting quarterly over the following three years. In the nine months ended September 30, 2022, 66,972 options were awarded to the Company's non-executive directors, with the majority vesting after one year from the date of grant.

The weighted average fair value and exercise prices of options granted is set out below.

	For the three months ended September 30,				For the nine months ended September 30,
	2022		2021		2022		2021
		$		$		$		$
Weighted average exercise price		37.25		39.02		25.49		26.19
Weighted average fair value		23.58		23.69		15.63		16.28

As at September 30, 2022, and 2021, there were 9,942,203 and 9,199,742 outstanding options, respectively, of which 4,661,406 and 2,506,791 respectively, were exercisable.

12. Trade and other payables

	September 30, 2022 £’000		December 31, 2021 £’000
Trade payables		10,042		7,499
Other taxation and social security		1,423		532
Accruals		53,078		27,382
Other payables		385		23
		64,928		35,436

Accruals include estimates for rebates, chargebacks, other customer fees and returns in respect of product revenue from the sale of KIMMTRAK and pre-product revenue from the sale of tebentafusp.

13. Events after the reporting period

On November 8, 2022, the Group entered into the Pharmakon Loan Agreement, providing for term loans to the Group in an aggregate principal amount of up to $100 million to be funded in two tranches. The first tranche, in the amount of $50 million, bears interest at a fixed rate of 9.75% and will mature in 6 years of draw. The Group used the proceeds from the first tranche, together with cash on hand, to repay in full the Group's existing $50 million loan from Oxford Finance and thereafter no further amounts may be borrowed pursuant to the loan agreement with Oxford Finance. The second tranche, consisting of one or two term loan(s) in an aggregate principal amount of up to $50 million (with a minimum draw of $25 million), is available until June 30, 2024 and may be advanced at the Group's election and, if and when drawn, is intended to be used to support the continued development and commercialization of the Company's pipeline and for other general purposes.

On November 7, 2022, the Group and Medison Pharma Ltd (“Medison”) amended their exclusive distribution agreement from September 2021. Under the agreement, Medison will obtain all required marketing authorizations not currently obtained to date, market and distribute KIMMTRAK in Canada, Australia, New Zealand, Israel, Central and Eastern Europe, and, following the amendment, South and Central America, and the Caribbean. Under the distribution agreement, Medison is responsible for regulatory, sales and marketing, and distribution channel costs, and it receives a portion of net sales. Additionally, under the amended distribution agreement, Medison will pay the Group a non-refundable upfront fee of $5 million which the Group expects to receive in the three months ended December 31, 2022.

EX-101.SCH 3 imcr-20220930.xsd XBRL SCHEMA FILE 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Unaudited Condensed Consolidated Statements of Profit / (Loss) and Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Unaudited Condensed Consolidated Statements of Financial Position link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Unaudited Condensed Consolidated Statements of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Organization and nature of business link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Significant accounting policies link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Selling and Administrative Expenses link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Finance costs link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Income tax link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Basic and diluted profit / (loss) per share link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Trade and other receivables link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - Capital and reserves link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - Share-based payments link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - Trade and other payables link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - Events after the reporting period link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - Significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Finance costs (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Basic and diluted profit / (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - Trade and other receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - Capital and reserves (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - Share-based payments (Tables) link:presentationLink link:calculationLink link:definitionLink 081200 - Disclosure - Trade and other payables (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - Organization and nature of business (Details) link:presentationLink link:calculationLink link:definitionLink 090204 - Disclosure - Significant accounting policies, Going concern (Details) link:presentationLink link:calculationLink link:definitionLink 090214 - Disclosure - Significant accounting policies, Product revenue, net (Details) link:presentationLink link:calculationLink link:definitionLink 090216 - Disclosure - Significant accounting policies, Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Revenue, Revenue recognised (Details) link:presentationLink link:calculationLink link:definitionLink 090302 - Disclosure - Revenue, Collaboration (Details) link:presentationLink link:calculationLink link:definitionLink 090304 - Disclosure - Revenue, Deferred revenue (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Selling and Administrative Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Finance costs (Details) link:presentationLink link:calculationLink link:definitionLink 090606 - Disclosure - Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Basic and diluted profit / (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Trade and other receivables (Details) link:presentationLink link:calculationLink link:definitionLink 090902 - Disclosure - Leases, (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - Capital and reserves, Shares Issued (Details) link:presentationLink link:calculationLink link:definitionLink 091002 - Disclosure - Capital and reserves, Issued share capital (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - Share-based payments (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - Trade and other payables (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - Events after the reporting period (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 imcr-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 5 imcr-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 6 imcr-20220930_lab.xml XBRL LABEL FILE Unused tax credits [Member] Other Reserve [Member] Top of Range [Member] Top of range [member] Selling and Administrative Expense [Member] Equity attributable to owners of parent [member] Related parties [member] Share Premium [Member] Share-based Payment Reserve [Member] Entity's total for related parties [member] Share Capital [Member] Issued capital [member] Non-adjusting events after reporting period [member] Products and services [member] Equity [member] Share Capital [Member] Share capital [member] Ranges [member] Temporary difference, unused tax losses and unused tax credits [member] Foreign Currency Translation Reserve [Member] Bottom of Range [Member] Bottom of range [member] Borrowings by name [member] Accumulated Deficit [Member] Retained earnings [member] Geographical areas [member] Line items by function [member] Ordinary Shares [Member] Ordinary shares [member] Exercise of share options Issued share capital Research and development tax credit Contingent liability Selling and administrative expenses [Abstract] Inventory Net taxation paid Current liabilities Current liabilities [abstract] Diluted weighted average number of shares (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Revenue Disclosure of revenue [text block] Deferred revenue Current contract liabilities Increase in trade and other payables Foreign exchange gain (loss) [abstract] Disclosure of non-adjusting events after reporting period [line items] Other receivables Other working capital movements Number of shares issued (in shares) Number of shares issued (in shares) Basic and diluted profit / (loss) per share Unaudited Condensed Consolidated Statements of Changes in Equity [Abstract] Gross proceeds from issue of share capital Interest-bearing loans and borrowings Lease liabilities Non-current lease liabilities Cash flows used in investing activities Share premium Other comprehensive loss that is or may be reclassified to profit or loss in subsequent periods: Awards granted, number of share options (in shares) Number of share options granted in share-based payment arrangement Other investing activities Disclosure of operating segments [line items] Costs from issue of share capital Payments for share issue costs Revenue receivable for R&D word done Leases Disclosure of leases [text block] Deferred revenue [Abstract] Trade payables Current trade payables Total current assets Current assets Disclosure of detailed information about borrowings [line items] Foreign currency translation reserve Significant accounting policies Basic weighted average number of shares (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Adjustments for: Trade and other payables Trade and other payables Disclosure of attribution of expenses by nature to their function [line items] Other non-current assets Other non-current financial assets Repayment of lease liabilities Payments of lease liabilities, classified as financing activities Share-based payments [Abstract] Deferred revenue Non-current contract liabilities Basic and diluted profit/ (loss) [Abstract] Disclosure of detailed information about business combination [line items] Offering expenses Offering expenses Net cash flows used in investing activities Cash flows from (used in) investing activities Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Issue of share capital Operating profit/(loss) Operating profit / (loss) Trade and other receivables Trade and other current receivables Net cash flows from financing activities Cash flows from (used in) financing activities Other taxation and social security Current payables on social security and taxes other than income tax Trade receivables Other comprehensive loss Other comprehensive income [abstract] Proceeds from shares issued Gross proceeds Proceeds from shares issued Changes in equity Other Other adjustments to reconcile profit (loss) Profit / (loss) before taxation Profit (loss) before tax Tax receivable Disclosure of disaggregation of revenue from contracts with customers [line items] Proceeds from sale of property, plant and equipment Proceeds from sales of property, plant and equipment, classified as investing activities Revenue recognized Disclosure of operating segments [text block] Accruals Accruals classified as current Total trade and other receivables Trade and other receivables Income tax credit Income tax credit Tax expense (income) Lease liabilities Total revenue Revenue Beginning balance Ending balance Total equity Equity Revenue recognized Total liabilities Liabilities Equity Equity [abstract] Non-operating expense Finance income (cost) Interest expense on borrowings Net cash used in operating activities Net cash used in operating activities Income tax [Abstract] Cash and cash equivalents Cash and cash equivalents at end of the period Cash and cash equivalents at beginning of the year Cash and cash equivalents Share-based payment charge Equity settled share-based payment expense Depreciation Total comprehensive loss for the period Comprehensive income Basic and diluted profit / (loss) per share Earnings per share [text block] Provisions Non-current provisions Deferred tax asset Statement of changes in equity [line items] Total revenue from sale of therapies Net product and net pre-product revenue Total revenue from sale of therapies Weighted average exercise price (in dollars per share) Weighted average exercise price of share options exercised in share-based payment arrangement Increase in receivables and other non-current assets Proceeds from investment in sub-leases Proceeds from sales or maturity of financial instruments, classified as investing activities Selling and administrative expenses Selling, general and administrative expense Events after the reporting period [Abstract] Total assets Assets Share-based payment reserve Trade and other payables Disclosure of trade and other payables [text block] Interest expense Leases [Abstract] Par value per share (in pounds per share) Weighted average fair value and exercise prices of options granted Disclosure of number and weighted average exercise prices of share options [text block] Unaudited Condensed Consolidated Statements of Cash Flows [Abstract] Cash flows from financing activities Increase in cash and cash equivalents Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Net current assets Number of shares outstanding at end of period (in shares) Number of shares outstanding at beginning of period (in shares) Number of shares outstanding Finance costs Disclosure of finance cost [text block] Purchase of property, plant and equipment Purchase of property, plant and equipment, classified as investing activities Prepayments and accrued income Prepayments and accrued income other than contract assets Basic earnings / (loss) per share (in pounds per share) Basic earnings / (loss) per share (in pounds per share) Disclosure of terms and conditions of share-based payment arrangement [line items] Share-based payments Disclosure of share-based payment arrangements [text block] Unaudited Condensed Consolidated Statements of Financial Position [Abstract] Net finance costs (non-operating expense) Adjustments for finance income (cost) Inventory write down, amount Inventory write-down Interest paid on non-current interest-bearing loan Repayments of non-current borrowings Accumulated deficit Repayment of debt Repayment of debt Adjustment for stock options with dilutive effect (in shares) Dilutive effect of share options on number of ordinary shares Profit / (loss) for the period Loss for the period Profit / (loss) for the period Tax rate [Abstract] Property, plant and equipment Interest expenses on financial liabilities measured at amortized cost Interest expense for financial liabilities not at fair value through profit or loss Events after the reporting period Trade and other receivables [Abstract] Interest on lease liabilities (see Note 12) Interest expense on lease liabilities Non-current liabilities Non-current liabilities [abstract] Research and development costs Research and development expense Total non-current liabilities Non-current liabilities EX-101.PRE 7 imcr-20220930_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2022
Cover [Abstract]
Document Type	6-K/A
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Current Fiscal Year End Date	--12-31
Entity Registrant Name	Immunocore Holdings plc
Entity Central Index Key	0001671927

XML 9 R2.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Profit / (Loss) and Other Comprehensive Loss - GBP (£)

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Unaudited Condensed Consolidated Statements of Profit / (Loss) and Other Comprehensive Loss [Abstract]

Product revenue, net

£ 33,252,000

£ 0

£ 64,926,000

£ 0

Pre-product revenue, net

3,051,000

474,000

9,588,000

474,000

Total revenue from sale of therapies

36,303,000

474,000

74,514,000

474,000

Collaboration revenue

4,896,000

5,450,000

21,161,000

19,453,000

Total revenue

41,199,000

5,924,000

95,675,000

19,927,000

Cost of product revenue

(63,000)

(345,000)

Research and development costs

(23,301,000)

(16,798,000)

(62,032,000)

(53,154,000)

Selling and administrative expenses

(11,663,000)

(20,048,000)

(50,580,000)

(64,033,000)

Net other operating (expense) / income

(28,000)

1,000

(70,000)

Operating profit / (loss)

6,172,000

(30,950,000)

(17,281,000)

(97,330,000)

Finance income

597,000

8,000

725,000

42,000

Finance costs

(1,785,000)

(1,317,000)

(4,515,000)

(4,465,000)

Non-operating expense

(1,188,000)

(1,309,000)

(3,790,000)

(4,423,000)

Profit / (loss) before taxation

4,984,000

(32,259,000)

(21,071,000)

(101,753,000)

Income tax credit

1,244,000

2,125,000

5,050,000

9,619,000

Profit / (loss) for the period

6,228,000

(30,134,000)

(16,021,000)

(92,134,000)

Other comprehensive loss that is or may be reclassified to profit or loss in subsequent periods:

Exchange differences on translation of foreign operations

(1,730,000)

(38,000)

(1,848,000)

(92,000)

Total Other comprehensive loss for the period

(1,730,000)

(38,000)

(1,848,000)

(92,000)

Total comprehensive loss for the period

£ 4,498,000

£ (30,172,000)

£ (17,869,000)

£ (92,226,000)

Basic earnings / (loss) per share (in pounds per share)

^[1]

£ 0.13

£ (0.69)

£ (0.36)

£ (2.19)

Diluted earnings / (loss) per share (in pounds per share)

^[1]

£ 0.12

£ (0.69)

£ (0.36)

£ (2.19)

[1]

Basic profit / (loss) per share is calculated by dividing the profit or loss for the period attributable to the equity holders of the Group by the weighted average number of ordinary shares outstanding during the period, including ordinary shares represented by ADSs. Except for the three months ended September 30, 2022, the dilutive effect of potential shares through equity settled transactions is considered to be anti-dilutive as they would decrease the loss per share and are, therefore, excluded from the calculation of diluted loss per share. For the three months ended September 30, 2022, there were 88,695 of the potential ordinary shares granted under the Group’s option plans excluded from the calculation for diluted options per share, because they are considered to be anti-dilutive.

XML 10 R3.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Financial Position - GBP (£)	Sep. 30, 2022	Dec. 31, 2021
Non-current assets
Property, plant and equipment	£ 6,580,000	£ 8,944,000
Right of use assets	23,963,000	22,593,000
Other non-current assets	6,749,000	4,935,000
Deferred tax asset	3,860,000	2,575,000
Total non-current assets	41,152,000	39,047,000
Current assets
Inventory	854,000	0
Trade and other receivables	40,968,000	15,208,000
Tax receivable	14,510,000	9,632,000
Cash and cash equivalents	347,189,000	237,886,000
Total current assets	403,521,000	262,726,000
Total assets	444,673,000	301,773,000
Equity
Share capital	96,000	88,000
Share premium	120,147,000	212,238,000
Foreign currency translation reserve	(1,759,000)	89,000
Other reserves	337,847,000	386,167,000
Share-based payment reserve	74,538,000	54,357,000
Accumulated deficit	(236,050,000)	(481,392,000)
Total equity	294,819,000	171,547,000
Non-current liabilities
Interest-bearing loans and borrowings	45,563,000	37,226,000
Deferred revenue	0	6,408,000
Lease liabilities	26,965,000	25,355,000
Provisions	108,000	57,000
Total non-current liabilities	72,636,000	69,046,000
Current liabilities
Trade and other payables	64,928,000	35,436,000
Deferred revenue	10,681,000	24,450,000
Lease liabilities	1,553,000	1,255,000
Provisions	56,000	39,000
Total current liabilities	77,218,000	61,180,000
Total liabilities	149,854,000	130,226,000
Total equity and liabilities	£ 444,673,000	£ 301,773,000

XML 11 R4.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Changes in Equity - GBP (£) £ in Thousands	Total	Share Capital [Member]	Share Premium [Member]	Foreign Currency Translation Reserve [Member]	Share-based Payment Reserve [Member]	Other Reserve [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020	£ 55,346	£ 64	£ 0	£ 163	£ 18,821	£ 386,167	£ (349,869)
Changes in equity
Loss for the period	(92,134)	0	0	0	0	0	(92,134)
Other comprehensive loss	(92)	0	0	(92)	0	0	0
Total comprehensive loss for the period	(92,226)	0	0	(92)	0	0	(92,134)
Issue of share capital	210,985	24	210,961	0	0	0	0
Exercise of share options	644	0	644	0	0	0	0
Equity-settled share-based payment transactions	27,138	0	325	0	26,813	0	0
Ending balance at Sep. 30, 2021	201,887	88	211,930	71	45,634	386,167	(442,003)
Beginning balance at Dec. 31, 2021	171,547	88	212,238	89	54,357	386,167	(481,392)
Changes in equity
Loss for the period	(16,021)	0	0	0	0	0	(16,021)
Other comprehensive loss	(1,848)	0	0	(1,848)	0	0	0
Total comprehensive loss for the period	(17,869)	0	0	(1,848)	0	0	(16,021)
Capital reduction in Group's parent company	0	0	(213,043)	0	0	(48,320)	261,363
Issue of share capital	116,424	7	116,417	0	0	0	0
Exercise of share options	4,536	1	4,535	0	0	0	0
Equity-settled share-based payment transactions	20,181	0	0	0	20,181	0	0
Ending balance at Sep. 30, 2022	£ 294,819	£ 96	£ 120,147	£ (1,759)	£ 74,538	£ 337,847	£ (236,050)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2022-03-24
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2022-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2022-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2022-03-24
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2022-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2022-03-24

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2022-03-24
-Paragraph 39L
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2022-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2022-03-24
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard
-URIDate 2022-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2022-03-24
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2022-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2023-01-01
-Name IFRS
-Number 17
-IssueDate 2022-03-24
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2022-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2022-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2022-03-24

+ Details

XML 12 R5.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Statements of Cash Flows - GBP (£)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Loss for the period	£ (16,021,000)	£ (92,134,000)
Adjustments for:
Equity settled share-based payment expense	20,181,000	27,138,000
Depreciation	4,794,000	5,294,000
Net finance costs (non-operating expense)	3,790,000	4,423,000
Foreign exchange differences	(20,498,000)	320,000
Other	(1,000)	273,000
Income tax credit	(5,050,000)	(9,619,000)
Working capital adjustments:
Increase in receivables and other non-current assets	(25,021,000)	(1,684,000)
Increase in trade and other payables	27,501,000	3,085,000
Decrease in deferred revenue	(20,177,000)	(16,853,000)
Other working capital movements	(807,000)	(21,000)
Cash used in operations	(31,309,000)	(79,778,000)
Net taxation paid	(614,000)	0
Net cash used in operating activities	(31,923,000)	(79,778,000)
Cash flows used in investing activities
Proceeds from sale of property, plant and equipment	5,000	64,000
Purchase of property, plant and equipment	(869,000)	(730,000)
Proceeds from investment in sub-leases	0	549,000
Other investing activities	725,000	15,000
Net cash flows used in investing activities	(139,000)	(102,000)
Cash flows from financing activities
Gross proceeds from issue of share capital	116,812,000	226,528,000
Costs from issue of share capital	(388,000)	(15,543,000)
Exercise of share options	4,536,000	644,000
Interest paid on non-current interest-bearing loan	(3,050,000)	(2,473,000)
Repayment of lease liabilities	(2,265,000)	(2,465,000)
Net cash flows from financing activities	115,645,000	206,691,000
Increase in cash and cash equivalents	83,583,000	126,811,000
Net foreign exchange difference on cash	25,720,000	24,000
Cash and cash equivalents at beginning of the year	237,886,000	129,716,000
Cash and cash equivalents at end of the period	£ 347,189,000	£ 256,551,000

XML 13 R6.htm IDEA: XBRL DOCUMENT

Organization and nature of business	9 Months Ended
Organization and nature of business	Sep. 30, 2022
Organization and nature of business [Abstract]
Organization and nature of business	1. Organization and nature of business General information Immunocore Holdings plc (the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries: Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited (collectively referred to as the “Group”). The Company’s American Depositary Shares (“ADSs”) began trading on the Nasdaq Global Select Market under the ticker symbol “IMCR” on February 5, 2021, following its initial public offering (“IPO”). The IPO and concurrent private placement generated net proceeds of £210,985,000 after underwriting discounts, commissions and directly attributable offering expenses. In July 2022, the Company issued and sold a total of 3,733,333 ordinary shares to certain institutional accredited investors as a private investment in public entity (the “PIPE”) pursuant to a securities purchase agreement, generating proceeds of £116,812,000 ($140,000,000) before deductions for offering expenses of £388,000. The principal activity of the Group is pioneering the development and sale of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, the Group is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. In January and April 2022, the Group received approval from the U.S. Food and Drug Administration (“FDA”) and European Commission (“EC”), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma (“mUM”). In June 2022, the UK’s MHRA, Health Canada, and the Australian Government Department of Health’s TGA have each approved KIMMTRAK for the treatment of HLA-A*02:01-positive adult patients with unresectable or mUM. KIMMTRAK is now approved in over 30 countries with commercial launches underway in the U.S., Germany, France and Canada. The Group expects to obtain regulatory approval for KIMMTRAK in further territories in the next year.

XML 14 R7.htm IDEA: XBRL DOCUMENT

Significant accounting policies	9 Months Ended
Significant accounting policies	Sep. 30, 2022
Significant accounting policies [Abstract]
Significant accounting policies	2. Significant accounting policies Basis of preparation The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with International Accounting Standard 34, “Interim Financial Reporting” (“IAS 34”). Except as described in Significant Accounting Policies below, the accounting policies applied in these interim financial statements are the same as those applied in the Group’s consolidated financial statements as at and for the year ended December 31, 2021. The unaudited condensed consolidated interim financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Group for the year ended December 31, 2021 included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 3, 2022 (the “Annual Report”). New accounting policies applicable to the three and nine months ended September 30, 2022, are outlined further below. The unaudited condensed and consolidated interim financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in pounds sterling which is the Company’s functional currency. All values are rounded to the nearest thousand, except where otherwise indicated. Date of authorization These unaudited condensed consolidated interim financial statements were prepared at the request of the Company’s Board of Directors (the “Board”) and were approved by the Board on November 9, 2022, and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer of the Group. Adoption of new accounting standards There have been no new accounting standards adopted by the Group in 2022 which have had a material impact on these unaudited condensed consolidated interim financial statements. There are no standards issued but not yet effective that the Group expects to have a material impact on its financial statements. Going concern The Group reported cash and cash equivalents of £347,189,000 and net current assets of £326,303,000 as at September 30, 2022, with an operating profit / (loss) for the three and nine months ended September 30, 2022 of £6,172,000 and (£17,281,000), respectively, and net cash used in operating activities for the nine months ended September 30, 2022 of £31,923,000. The negative operational cash flow was largely due to the Group’s continued focus on research, development, and clinical activities to advance preclinical and clinical programs within the Group’s pipeline. The Group generated net product and net pre-product revenue totalling £36,303,000 and £74,514,000 during the three and nine months ended September 30, 2022, respectively. In July 2022, the Group received £116,812,000 ($140,000,000) before deduction of attributable expenses of £388,000 following the PIPE. In assessing the going concern assumptions, the Board has undertaken an assessment of the current business and strategy forecasts covering a two-year period, which includes anticipated KIMMTRAK revenue. In assessing the downside risks, the Board has also considered scenarios incorporating a range of revenue arising from KIMMTRAK sales. As part of considering the downside risks, the Board has considered the impact of the ongoing coronavirus 2019 (‘‘COVID-19’’) pandemic and other potential economic impacts including the war in Ukraine and related geopolitical tensions, as well as global inflation, capital market instability, exchange rate fluctuations, and increases in commodity, energy and fuel prices. The Board has concluded that while these may have a future impact on the Group’s business and implementation of its strategy and plans, it anticipates that any such impact will be minimal on clinical trials or other business activities over the period assessed for going concern purposes. As of the date of these financial statements, the Group is not aware of any specific event or circumstance that would require the Group to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Group’s financial statements. Given the current cash position and the assessment performed, the Board believes that the Group will have sufficient funds to continue to meet its liabilities as they fall due throughout the forecast period outlined above and therefore, the Group has prepared the financial statements on a going concern basis. This scenario is based on the Group’s lower range of anticipated revenue levels. As the Group continues to incur significant expenses in the pursuit of its business strategy, including further commercialization and marketing plans for KIMMTRAK, additional funding will be needed before further existing clinical and preclinical programs may be expected to reach commercialization, which would potentially lead to additional operational cash inflows. Until the Group can generate revenue from product sales sufficient to fund its ongoing operations and further develop its pipeline, if ever, it expects to finance its operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. Estimates and judgements The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as contingent liabilities and income and expenses in the financial period. The estimates and associated assumptions are based on information available when the unaudited condensed consolidated interim financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to market changes or circumstances arising that are beyond the Group’s control. Therefore, estimates may vary from eventual outcomes and may be subject to updates in future reported periods. Judgements and estimates made, together with our significant accounting policies, are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2021, and are presented in the Group’s Annual Report. Significant updates to the Group’s estimates and accounting policies for the three and nine months ended September 30, 2022 are outlined below. Critical Accounting Estimates Estimated rebates, chargebacks and product returns As outlined below in the “Product revenue, net” policy, the Group recognizes revenue net of estimated deductions for rebates, chargebacks, other customer fees and product returns. Due to its limited history of product sales in the United States having only recently received regulatory approval for its first product, the Group has limited directly comparable information of actual rebate claims, chargebacks or levels of product returns, and the Group’s early sales information may have limited predictive value. The Group uses the expected value method to estimate revenue deductions, which considers the likelihood of a rebate, chargeback or product return being applicable to sales. The proportion of sales subject to a rebate or chargeback, and the level of product returns, is inherently uncertain and the Group’s estimates are based on internal assumptions, which may change as the Group develops more product experience, and third-party data, which the Group assesses for reliability and relevance. Rebates and chargebacks The Group is subject to state government Medicaid programs and other qualifying federal and state programs in the United States requiring rebates to be paid to participating state and local government entities, depending on the eligibility and circumstances of patients treated with KIMMTRAK after the Group has sold vials to specialty distributors. The Group is also subject to chargebacks from its specialty distributors under the 340B program in the United States, whereby qualifying hospitals are entitled to purchase KIMMTRAK at a lower price. For such sales, the Group’s specialty distributors charge back the difference between the wholesale acquisition cost and this lower price. Estimating rebate and chargeback deductions from revenue is judgmental due to the time delay between the date of the sale to specialty distributors and the subsequent dates on which the Group is able to determine actual amounts of chargebacks and rebates. The Group forms estimates of 340B chargeback deductions by analyzing sell-through data relating to the hospital mix of onward sales made by specialty distributors. For Medicaid and other rebates, the Group forms estimates based on internal forecasts of the patient mix and external health coverage statistics. Judgment is applied to consider the relevance and reliability of information used to make these estimates. Judgment is also required in determining the amount of the Group’s net pre-product revenue and product revenue in France. Rebates payable to the Economic Committee for Health Products (“CEPS”) under compassionate use, early access and commercial programs are subject to a high degree of estimation uncertainty. The Group’s estimate of these rebates represents the difference between the expected agreed price for the commercial sale of KIMMTRAK in France, which is subject to price negotiation, and the initial price of tebentafusp and KIMMTRAK sold under early access and commercial programs until this price is agreed. Analysis of further legislative requirements, sales volumes and the expected benefit of KIMMTRAK to patients in France is also required in the assessment of rebates payable. The Group applies judgement to assess internal targets, pricing information of other therapies approved for sale in France, information obtained from price negotiations of KIMMTRAK in other countries, and information connected with KIMMTRAK’s safety profile when forming its estimated rebate deduction from revenue. Product returns The Group considers several inputs when estimating potential levels of product returns. Due to the nature of KIMMTRAK as a therapy, the Group expects no product returns following patient administration by trained healthcare professionals. The Group applies judgement in assessing the level of returns for sales made to distributors which have yet to be administered to patients. The Group considers industry average return levels, distributor sell-through rates, the levels of inventory in the distribution channel, the period of time for which inventory has been held by its distributors, the level of orders placed, the expiry date of products sold, and its distributors’ right to return products in the case of vials of KIMMTRAK with a shorter period to expiry. As orders are typically placed based on scheduled administration by hospitals and healthcare facilities, the Group does not expect a significant level of product returns. Significant Accounting Policies Product revenue, net Product revenue, net, relates to the sale of KIMMTRAK following marketing approval. The Group recognizes revenue at the point in time that control transfers to a customer, which is typically on delivery. The Group also operates under consignment arrangements where control passes when the Group’s distributor takes KIMMTRAK out of consignment inventory. The amount of revenue recognized under its arrangements reflects the consideration to which the Group expects to be entitled to, net of estimated deductions for rebates, chargebacks, other customer fees and product returns. Estimated revenue deductions are updated at the end of each reporting period using the latest available data. The Group considers whether any part of amounts expected to be received should be constrained to ensure that it is highly probable that a significant reversal in the cumulative revenue recognized will not occur. Estimating such deductions involves judgments which are detailed further above under “Critical accounting estimates”. The Group’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list prices with standard payment terms typically between one and two months. When the Group has the right to offset chargebacks against trade receivables and the parties have agreed to settle the payments net, chargebacks are recorded as a reduction in trade receivables. Other chargebacks, rebates and deductions are recognized as an accrual in the condensed consolidated statement of financial position. The Group’s customers are hospitals and healthcare providers in certain countries, where KIMMTRAK is sold through an agent acting on the Group’s behalf. Pre-product revenue, net Pre-product revenue, net, relates to the sale of tebentafusp under a compassionate use and an early access program in France up to September 2022. These programs provided patients with access to tebentafusp before KIMMTRAK became available as a marketed product in France. Pre-product revenue is recognized on delivery of tebentafusp to healthcare providers, which is the point in time when control is transferred. Such revenue is recognized net and represents the prices set by the Group that are expected to be retained after estimated deductions and to the extent that it is highly probable that a significant reversal of revenue will not occur. These variable estimated deductions include both an estimate of government rebates payable and an estimate of returns in the case of expiry, damage or other instances. The total rebate payable by the Group is dependent on the outcome of price negotiations with the French government, and the Group makes an estimate of these amounts payable each reporting period based on available pricing information and the applicable regulations. Returns are estimated based on industry trends and information provided by the Group’s distributors. The estimates for rebates and returns deducted from pre-product revenue are recorded in the period the related pre-product revenue is recognized and are classified under Accruals within Trade and other payables in the Condensed Consolidated Statement of Financial Position. Costs of pre-product revenue are expensed when incurred and include costs associated with previous manufacturing of tebentafusp and other third-party selling expenses. Previous manufacturing costs were recognized in Research and development expenses at the time, and third-party selling expenses are recognized within Selling and administrative expenses. Cost of product revenue Cost of product revenue represents production costs including raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale. Due to the Group’s manufacturing arrangements, overheads and internal costs of product revenue are minimal. Further information on Cost of product revenue is included within the ‘Inventories’ policy below. Trade Receivables Trade receivables include amounts invoiced or contractually accrued where only the passage of time is required before payment is received under the Group’s collaboration agreements and other revenue arrangements. Trade receivables are assessed for impairment using the simplified approach under IFRS 9, Financial Instruments, which requires lifetime expected losses to be recognized with the initial recognition of the receivable. Due to its lack of sales history, the Group estimates expected credit losses using internal information, industry credit default information, and comparable information available from companies with similar customers. As of September 30, 2022, the amount of expected credit losses is not material. Inventories Inventories include finished goods manufactured for commercial sale, items in the process of being manufactured for commercial sale, and the materials to be used in the manufacturing process. The principal costs in manufacturing the Group’s inventories are raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale. Inventories are measured at weighted average cost and presented as assets in the Condensed Consolidated Statement of Financial Position to the extent that they are recoverable. Inventories are stated at the lower of cost and net realizable value, and the Group assesses whether an expense should be recognized to write down inventory values at each reporting period. Where this expense relates to inventories manufactured or developed following marketing approval of KIMMTRAK, the Group recognizes the expense within Cost of product revenue. Prior to receiving marketing approval, the Group recorded the expense for prelaunch inventory expected to be sold in the ordinary course of business within Research and development expenses. Reversals of previous write-downs of inventories are recognized within Cost of product revenue or Research and development expenses, depending on where the write-down was originally recognized. As at September 30, 2022, the Group held a provision against the value of its inventories of £701,000, of which £185,000 has been recognized in Cost of product revenue in the Condensed Consolidated Statement of Profit / (Loss) and Comprehensive Loss in the nine months ended September 30, 2022. Due to the low costs involved in manufacturing KIMMTRAK, inventory costs and Cost of product revenue are not material at this time, and the Group does not expect these costs to be material for the foreseeable future.

XML 15 R8.htm IDEA: XBRL DOCUMENT

Revenue

9 Months Ended

Sep. 30, 2022

Revenue [Abstract]

Revenue

3. Revenue

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000

Product revenue, net		33,252		—		64,926		—
Pre-product revenue, net		3,051		474		9,588		474
Total revenue from sale of therapies		36,303		474		74,514		474
Collaboration revenue
GSK		—		1,263		—		5,919
Eli Lilly		—		—		7,361		—
Genentech		4,896		4,187		13,800		13,534
Total collaboration revenue		4,896		5,450		21,161		19,453
Total revenue		41,199		5,924		95,675		19,927

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000
United States		22,508		—		48,327		—
Europe		13,034		474		25,423		474
Rest of World		761		—		764		—
Total revenue from sale of therapies		36,303		474		74,514		474

Product revenue, net

Pre-product revenue, net

Genentech Collaboration

GSK Collaboration

Eli Lilly Collaboration

Deferred revenue

XML 16 R9.htm IDEA: XBRL DOCUMENT

Selling and Administrative Expenses	9 Months Ended
Selling and Administrative Expenses	Sep. 30, 2022
Selling and administrative expenses [Abstract]
Selling and administrative expenses	4. Selling and administrative expenses There were £15,184,000 and £24,343,000, respectively, of foreign exchange gains, which the Group classifies within Selling and administrative expenses, for the three and nine months ended September 30, 2022, compared to gains of £3,338,000 and £1,080,000 in the three and nine months ended September 30, 2021. These gains arise on a number of foreign currency items, and the translation of monetary foreign currency balances in the Group’s main operating subsidiary in the United Kingdom has been significantly impacted by changes in exchange rates between pounds sterling and U.S. dollars in the three months ended September 30, 2022. The Group periodically assesses its exposure to foreign currency fluctuations and, to the extent practical, seeks to minimize foreign currency risk by maintaining cash and cash equivalents of each currency at levels sufficient to meet foreseeable expenditure. The Group has not to date entered into hedging instruments to reduce the impact of foreign currency fluctuations, but it may do so in the future.

XML 17 R10.htm IDEA: XBRL DOCUMENT

Finance costs

9 Months Ended

Sep. 30, 2022

Finance costs [Abstract]

Finance costs

5. Finance costs

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000
Interest expense on lease liabilities		461		428		1,316		1,301
Interest expense on financial liabilities measured at amortized cost		1,324		889		3,199		3,164
		1,785		1,317		4,515		4,465

XML 18 R11.htm IDEA: XBRL DOCUMENT

Income tax	9 Months Ended
Income tax	Sep. 30, 2022
Income tax [Abstract]
Income tax	6. Income tax An income tax credit is recognized at an amount determined by multiplying the loss before taxation for the interim reporting period by the Group’s best estimate of the estimated annual income tax credit rate expected for the full financial year, adjusted for the tax effect of certain items recognized in full in the interim period. As such, the effective tax credit rate in the interim financial statements may differ from the Group’s estimate of the effective tax credit rate for the annual financial statements. The Group’s consolidated estimated effective tax credit rate for the nine months ended September 30, 2022 was 24.0% (for the nine months ended September 30, 2021: 9.5%). During the nine months ended September 30, 2022, the Company recorded a tax credit of £5,050,000 related to its research and development tax credits in the United Kingdom and the income tax obligations of its operating companies in the U.S. and the Republic of Ireland, which generate profit for tax purposes. A deferred tax asset of £3,860,000 has been recognized as of September 30, 2022 (December 31, 2021: £2,575,000) representing unused tax credits and capitalized research and development costs carried forward for one of the Group’s subsidiaries, Immunocore LLC, following a periodic assessment of all available and applicable information, including its forecasts of costs and future profitability and the resulting ability to utilise the recognized deferred tax assets over a short period of time.

XML 19 R12.htm IDEA: XBRL DOCUMENT

Basic and diluted profit / (loss) per share

9 Months Ended

Sep. 30, 2022

Basic and diluted profit / (loss) per share [Abstract]

Basic and diluted profit / (loss) per share

7. Basic and diluted profit / (loss) per share

	For the three months ended September 30,					For the nine months ended September 30,
	2022		2021			2022			2021
Profit / (loss) for the period (£’000s)		6,228		(30,134	)		(16,021	)		(92,134	)
Basic weighted average number of shares		46,998,420		43,796,084			44,944,827			42,030,746
Adjustment for stock options with dilutive effect		4,444,856		—			—			—
Diluted weighted average number of shares		51,443,276		43,796,084			44,944,827			42,030,746
Basic earnings / (loss) per share (£) (1)		0.13		(0.69	)		(0.36	)		(2.19	)
Diluted earnings / (loss) per share (£) (1)		0.12		(0.69	)		(0.36	)		(2.19	)

XML 20 R13.htm IDEA: XBRL DOCUMENT

Trade and other receivables

9 Months Ended

Sep. 30, 2022

Trade and other receivables [Abstract]

Trade and other receivables

8. Trade and other receivables

	September 30, 2022 £’000		December 31, 2021 £’000
Trade receivables		25,809		6,047
Other receivables		6,214		1,470
Prepayments and accrued income		8,945		7,691
		40,968		15,208

XML 21 R14.htm IDEA: XBRL DOCUMENT

Leases	9 Months Ended
Leases	Sep. 30, 2022
Leases [Abstract]
Leases	9. Leases On July 13, 2022, the Group entered into a new lease for additional laboratory space in the United Kingdom. The lease expires in 2042; however, it is freely terminable at the Group’s option at three points during the lease prior to the expiration date. The Group may be required to make total payments of up to £5,483,000 under the lease agreement. The lease was previously disclosed as a contingent liability of £1,122,000 as at December 31, 2021, which represented the minimum amount of mandatory payments if the Group became required to enter into the lease. In the three months ended September 30, 2022, the Group recognized an initial right-of-use asset and lease liability of £2,472,000 in the Condensed Consolidated Statement of Financial Position in relation to this lease.

XML 22 R15.htm IDEA: XBRL DOCUMENT

Capital and reserves

9 Months Ended

Sep. 30, 2022

Capital and Reserves [Abstract]

Capital and reserves

10. Capital and reserves

	Ordinary Shares		Deferred Shares
At January 1, 2022		43,862,850		5,793,501
New shares issued for cash		3,733,333		—
Exercise of share options		308,776		—
At September 30, 2022		47,904,959		5,793,501

XML 23 R16.htm IDEA: XBRL DOCUMENT

Share-based payments

9 Months Ended

Sep. 30, 2022

Share-based payments [Abstract]

Share-based payments

11. Share-based payments

The weighted average fair value and exercise prices of options granted is set out below.

	For the three months ended September 30,				For the nine months ended September 30,
	2022		2021		2022		2021
		$		$		$		$
Weighted average exercise price		37.25		39.02		25.49		26.19
Weighted average fair value		23.58		23.69		15.63		16.28

As at September 30, 2022, and 2021, there were 9,942,203 and 9,199,742 outstanding options, respectively, of which 4,661,406 and 2,506,791 respectively, were exercisable.

XML 24 R17.htm IDEA: XBRL DOCUMENT

Trade and other payables

9 Months Ended

Sep. 30, 2022

Trade and other payables [Abstract]

Trade and other payables

12. Trade and other payables

	September 30, 2022 £’000		December 31, 2021 £’000
Trade payables		10,042		7,499
Other taxation and social security		1,423		532
Accruals		53,078		27,382
Other payables		385		23
		64,928		35,436

Accruals include estimates for rebates, chargebacks, other customer fees and returns in respect of product revenue from the sale of KIMMTRAK and pre-product revenue from the sale of tebentafusp.

XML 25 R18.htm IDEA: XBRL DOCUMENT

Events after the reporting period	9 Months Ended
Events after the reporting period	Sep. 30, 2022
Events after the reporting period [Abstract]
Events after the reporting period	13. Events after the reporting period On November 8, 2022, the Group entered into the Pharmakon Loan Agreement, providing for term loans to the Group in an aggregate principal amount of up to $100 million to be funded in two tranches. The first tranche, in the amount of $50 million, bears interest at a fixed rate of 9.75% and will mature in 6 years of draw. The Group used the proceeds from the first tranche, together with cash on hand, to repay in full the Group's existing $50 million loan from Oxford Finance and thereafter no further amounts may be borrowed pursuant to the loan agreement with Oxford Finance. The second tranche, consisting of one or two term loan(s) in an aggregate principal amount of up to $50 million (with a minimum draw of $25 million), is available until June 30, 2024 and may be advanced at the Group's election and, if and when drawn, is intended to be used to support the continued development and commercialization of the Company's pipeline and for other general purposes. On November 7, 2022, the Group and Medison Pharma Ltd (“Medison”) amended their exclusive distribution agreement from September 2021. Under the agreement, Medison will obtain all required marketing authorizations not currently obtained to date, market and distribute KIMMTRAK in Canada, Australia, New Zealand, Israel, Central and Eastern Europe, and, following the amendment, South and Central America, and the Caribbean. Under the distribution agreement, Medison is responsible for regulatory, sales and marketing, and distribution channel costs, and it receives a portion of net sales. Additionally, under the amended distribution agreement, Medison will pay the Group a non-refundable upfront fee of $5 million which the Group expects to receive in the three months ended December 31, 2022.

XML 26 R19.htm IDEA: XBRL DOCUMENT

Significant accounting policies (Policies)	9 Months Ended
Significant accounting policies (Policies)	Sep. 30, 2022
Significant accounting policies [Abstract]
Basis of preparation	Basis of preparation The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with International Accounting Standard 34, “Interim Financial Reporting” (“IAS 34”). Except as described in Significant Accounting Policies below, the accounting policies applied in these interim financial statements are the same as those applied in the Group’s consolidated financial statements as at and for the year ended December 31, 2021. The unaudited condensed consolidated interim financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Group for the year ended December 31, 2021 included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 3, 2022 (the “Annual Report”). New accounting policies applicable to the three and nine months ended September 30, 2022, are outlined further below. The unaudited condensed and consolidated interim financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in pounds sterling which is the Company’s functional currency. All values are rounded to the nearest thousand, except where otherwise indicated.
Date of authorization	Date of authorization These unaudited condensed consolidated interim financial statements were prepared at the request of the Company’s Board of Directors (the “Board”) and were approved by the Board on November 9, 2022, and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer of the Group.
Adoption of new accounting standards	Adoption of new accounting standards There have been no new accounting standards adopted by the Group in 2022 which have had a material impact on these unaudited condensed consolidated interim financial statements. There are no standards issued but not yet effective that the Group expects to have a material impact on its financial statements.
Going concern	Going concern The Group reported cash and cash equivalents of £347,189,000 and net current assets of £326,303,000 as at September 30, 2022, with an operating profit / (loss) for the three and nine months ended September 30, 2022 of £6,172,000 and (£17,281,000), respectively, and net cash used in operating activities for the nine months ended September 30, 2022 of £31,923,000. The negative operational cash flow was largely due to the Group’s continued focus on research, development, and clinical activities to advance preclinical and clinical programs within the Group’s pipeline. The Group generated net product and net pre-product revenue totalling £36,303,000 and £74,514,000 during the three and nine months ended September 30, 2022, respectively. In July 2022, the Group received £116,812,000 ($140,000,000) before deduction of attributable expenses of £388,000 following the PIPE. In assessing the going concern assumptions, the Board has undertaken an assessment of the current business and strategy forecasts covering a two-year period, which includes anticipated KIMMTRAK revenue. In assessing the downside risks, the Board has also considered scenarios incorporating a range of revenue arising from KIMMTRAK sales. As part of considering the downside risks, the Board has considered the impact of the ongoing coronavirus 2019 (‘‘COVID-19’’) pandemic and other potential economic impacts including the war in Ukraine and related geopolitical tensions, as well as global inflation, capital market instability, exchange rate fluctuations, and increases in commodity, energy and fuel prices. The Board has concluded that while these may have a future impact on the Group’s business and implementation of its strategy and plans, it anticipates that any such impact will be minimal on clinical trials or other business activities over the period assessed for going concern purposes. As of the date of these financial statements, the Group is not aware of any specific event or circumstance that would require the Group to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Group’s financial statements. Given the current cash position and the assessment performed, the Board believes that the Group will have sufficient funds to continue to meet its liabilities as they fall due throughout the forecast period outlined above and therefore, the Group has prepared the financial statements on a going concern basis. This scenario is based on the Group’s lower range of anticipated revenue levels. As the Group continues to incur significant expenses in the pursuit of its business strategy, including further commercialization and marketing plans for KIMMTRAK, additional funding will be needed before further existing clinical and preclinical programs may be expected to reach commercialization, which would potentially lead to additional operational cash inflows. Until the Group can generate revenue from product sales sufficient to fund its ongoing operations and further develop its pipeline, if ever, it expects to finance its operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements.
Estimates and judgements	Estimates and judgements The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as contingent liabilities and income and expenses in the financial period. The estimates and associated assumptions are based on information available when the unaudited condensed consolidated interim financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to market changes or circumstances arising that are beyond the Group’s control. Therefore, estimates may vary from eventual outcomes and may be subject to updates in future reported periods. Judgements and estimates made, together with our significant accounting policies, are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2021, and are presented in the Group’s Annual Report. Significant updates to the Group’s estimates and accounting policies for the three and nine months ended September 30, 2022 are outlined below.
Critical Accounting Estimates	Critical Accounting Estimates Estimated rebates, chargebacks and product returns As outlined below in the “Product revenue, net” policy, the Group recognizes revenue net of estimated deductions for rebates, chargebacks, other customer fees and product returns. Due to its limited history of product sales in the United States having only recently received regulatory approval for its first product, the Group has limited directly comparable information of actual rebate claims, chargebacks or levels of product returns, and the Group’s early sales information may have limited predictive value. The Group uses the expected value method to estimate revenue deductions, which considers the likelihood of a rebate, chargeback or product return being applicable to sales. The proportion of sales subject to a rebate or chargeback, and the level of product returns, is inherently uncertain and the Group’s estimates are based on internal assumptions, which may change as the Group develops more product experience, and third-party data, which the Group assesses for reliability and relevance. Rebates and chargebacks The Group is subject to state government Medicaid programs and other qualifying federal and state programs in the United States requiring rebates to be paid to participating state and local government entities, depending on the eligibility and circumstances of patients treated with KIMMTRAK after the Group has sold vials to specialty distributors. The Group is also subject to chargebacks from its specialty distributors under the 340B program in the United States, whereby qualifying hospitals are entitled to purchase KIMMTRAK at a lower price. For such sales, the Group’s specialty distributors charge back the difference between the wholesale acquisition cost and this lower price. Estimating rebate and chargeback deductions from revenue is judgmental due to the time delay between the date of the sale to specialty distributors and the subsequent dates on which the Group is able to determine actual amounts of chargebacks and rebates. The Group forms estimates of 340B chargeback deductions by analyzing sell-through data relating to the hospital mix of onward sales made by specialty distributors. For Medicaid and other rebates, the Group forms estimates based on internal forecasts of the patient mix and external health coverage statistics. Judgment is applied to consider the relevance and reliability of information used to make these estimates. Judgment is also required in determining the amount of the Group’s net pre-product revenue and product revenue in France. Rebates payable to the Economic Committee for Health Products (“CEPS”) under compassionate use, early access and commercial programs are subject to a high degree of estimation uncertainty. The Group’s estimate of these rebates represents the difference between the expected agreed price for the commercial sale of KIMMTRAK in France, which is subject to price negotiation, and the initial price of tebentafusp and KIMMTRAK sold under early access and commercial programs until this price is agreed. Analysis of further legislative requirements, sales volumes and the expected benefit of KIMMTRAK to patients in France is also required in the assessment of rebates payable. The Group applies judgement to assess internal targets, pricing information of other therapies approved for sale in France, information obtained from price negotiations of KIMMTRAK in other countries, and information connected with KIMMTRAK’s safety profile when forming its estimated rebate deduction from revenue. Product returns The Group considers several inputs when estimating potential levels of product returns. Due to the nature of KIMMTRAK as a therapy, the Group expects no product returns following patient administration by trained healthcare professionals. The Group applies judgement in assessing the level of returns for sales made to distributors which have yet to be administered to patients. The Group considers industry average return levels, distributor sell-through rates, the levels of inventory in the distribution channel, the period of time for which inventory has been held by its distributors, the level of orders placed, the expiry date of products sold, and its distributors’ right to return products in the case of vials of KIMMTRAK with a shorter period to expiry. As orders are typically placed based on scheduled administration by hospitals and healthcare facilities, the Group does not expect a significant level of product returns.
Significant Accounting Policies	Significant Accounting Policies Product revenue, net Product revenue, net, relates to the sale of KIMMTRAK following marketing approval. The Group recognizes revenue at the point in time that control transfers to a customer, which is typically on delivery. The Group also operates under consignment arrangements where control passes when the Group’s distributor takes KIMMTRAK out of consignment inventory. The amount of revenue recognized under its arrangements reflects the consideration to which the Group expects to be entitled to, net of estimated deductions for rebates, chargebacks, other customer fees and product returns. Estimated revenue deductions are updated at the end of each reporting period using the latest available data. The Group considers whether any part of amounts expected to be received should be constrained to ensure that it is highly probable that a significant reversal in the cumulative revenue recognized will not occur. Estimating such deductions involves judgments which are detailed further above under “Critical accounting estimates”. The Group’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list prices with standard payment terms typically between one and two months. When the Group has the right to offset chargebacks against trade receivables and the parties have agreed to settle the payments net, chargebacks are recorded as a reduction in trade receivables. Other chargebacks, rebates and deductions are recognized as an accrual in the condensed consolidated statement of financial position. The Group’s customers are hospitals and healthcare providers in certain countries, where KIMMTRAK is sold through an agent acting on the Group’s behalf. Pre-product revenue, net Pre-product revenue, net, relates to the sale of tebentafusp under a compassionate use and an early access program in France up to September 2022. These programs provided patients with access to tebentafusp before KIMMTRAK became available as a marketed product in France. Pre-product revenue is recognized on delivery of tebentafusp to healthcare providers, which is the point in time when control is transferred. Such revenue is recognized net and represents the prices set by the Group that are expected to be retained after estimated deductions and to the extent that it is highly probable that a significant reversal of revenue will not occur. These variable estimated deductions include both an estimate of government rebates payable and an estimate of returns in the case of expiry, damage or other instances. The total rebate payable by the Group is dependent on the outcome of price negotiations with the French government, and the Group makes an estimate of these amounts payable each reporting period based on available pricing information and the applicable regulations. Returns are estimated based on industry trends and information provided by the Group’s distributors. The estimates for rebates and returns deducted from pre-product revenue are recorded in the period the related pre-product revenue is recognized and are classified under Accruals within Trade and other payables in the Condensed Consolidated Statement of Financial Position. Costs of pre-product revenue are expensed when incurred and include costs associated with previous manufacturing of tebentafusp and other third-party selling expenses. Previous manufacturing costs were recognized in Research and development expenses at the time, and third-party selling expenses are recognized within Selling and administrative expenses. Cost of product revenue Cost of product revenue represents production costs including raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale. Due to the Group’s manufacturing arrangements, overheads and internal costs of product revenue are minimal. Further information on Cost of product revenue is included within the ‘Inventories’ policy below.
Trade Receivables	Trade Receivables Trade receivables include amounts invoiced or contractually accrued where only the passage of time is required before payment is received under the Group’s collaboration agreements and other revenue arrangements. Trade receivables are assessed for impairment using the simplified approach under IFRS 9, Financial Instruments, which requires lifetime expected losses to be recognized with the initial recognition of the receivable. Due to its lack of sales history, the Group estimates expected credit losses using internal information, industry credit default information, and comparable information available from companies with similar customers. As of September 30, 2022, the amount of expected credit losses is not material.
Inventories	Inventories Inventories include finished goods manufactured for commercial sale, items in the process of being manufactured for commercial sale, and the materials to be used in the manufacturing process. The principal costs in manufacturing the Group’s inventories are raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale. Inventories are measured at weighted average cost and presented as assets in the Condensed Consolidated Statement of Financial Position to the extent that they are recoverable. Inventories are stated at the lower of cost and net realizable value, and the Group assesses whether an expense should be recognized to write down inventory values at each reporting period. Where this expense relates to inventories manufactured or developed following marketing approval of KIMMTRAK, the Group recognizes the expense within Cost of product revenue. Prior to receiving marketing approval, the Group recorded the expense for prelaunch inventory expected to be sold in the ordinary course of business within Research and development expenses. Reversals of previous write-downs of inventories are recognized within Cost of product revenue or Research and development expenses, depending on where the write-down was originally recognized. As at September 30, 2022, the Group held a provision against the value of its inventories of £701,000, of which £185,000 has been recognized in Cost of product revenue in the Condensed Consolidated Statement of Profit / (Loss) and Comprehensive Loss in the nine months ended September 30, 2022. Due to the low costs involved in manufacturing KIMMTRAK, inventory costs and Cost of product revenue are not material at this time, and the Group does not expect these costs to be material for the foreseeable future.

XML 27 R20.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

9 Months Ended

Sep. 30, 2022

Revenue [Abstract]

Revenue recognized

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000

Product revenue, net		33,252		—		64,926		—
Pre-product revenue, net		3,051		474		9,588		474
Total revenue from sale of therapies		36,303		474		74,514		474
Collaboration revenue
GSK		—		1,263		—		5,919
Eli Lilly		—		—		7,361		—
Genentech		4,896		4,187		13,800		13,534
Total collaboration revenue		4,896		5,450		21,161		19,453
Total revenue		41,199		5,924		95,675		19,927

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000
United States		22,508		—		48,327		—
Europe		13,034		474		25,423		474
Rest of World		761		—		764		—
Total revenue from sale of therapies		36,303		474		74,514		474

XML 28 R21.htm IDEA: XBRL DOCUMENT

Finance costs (Tables)

9 Months Ended

Sep. 30, 2022

Finance costs [Abstract]

Finance costs

	For the three months ended September 30,				For the nine months ended September 30,
	2022 £’000		2021 £’000		2022 £’000		2021 £’000
Interest expense on lease liabilities		461		428		1,316		1,301
Interest expense on financial liabilities measured at amortized cost		1,324		889		3,199		3,164
		1,785		1,317		4,515		4,465

XML 29 R22.htm IDEA: XBRL DOCUMENT

Basic and diluted profit / (loss) per share (Tables)

9 Months Ended

Sep. 30, 2022

Basic and diluted profit / (loss) per share [Abstract]

Basic and diluted profit / (loss) per share

	For the three months ended September 30,					For the nine months ended September 30,
	2022		2021			2022			2021
Profit / (loss) for the period (£’000s)		6,228		(30,134	)		(16,021	)		(92,134	)
Basic weighted average number of shares		46,998,420		43,796,084			44,944,827			42,030,746
Adjustment for stock options with dilutive effect		4,444,856		—			—			—
Diluted weighted average number of shares		51,443,276		43,796,084			44,944,827			42,030,746
Basic earnings / (loss) per share (£) (1)		0.13		(0.69	)		(0.36	)		(2.19	)
Diluted earnings / (loss) per share (£) (1)		0.12		(0.69	)		(0.36	)		(2.19	)

XML 30 R23.htm IDEA: XBRL DOCUMENT

Trade and other receivables (Tables)

9 Months Ended

Sep. 30, 2022

Trade and other receivables [Abstract]

Trade and other receivables

	September 30, 2022 £’000		December 31, 2021 £’000
Trade receivables		25,809		6,047
Other receivables		6,214		1,470
Prepayments and accrued income		8,945		7,691
		40,968		15,208

XML 31 R24.htm IDEA: XBRL DOCUMENT

Capital and reserves (Tables)

9 Months Ended

Sep. 30, 2022

Capital and Reserves [Abstract]

Issued share capital

The table below shows the movement in the number of issued shares during the nine months ended September 30, 2022.

	Ordinary Shares		Deferred Shares
At January 1, 2022		43,862,850		5,793,501
New shares issued for cash		3,733,333		—
Exercise of share options		308,776		—
At September 30, 2022		47,904,959		5,793,501

XML 32 R25.htm IDEA: XBRL DOCUMENT

Share-based payments (Tables)

9 Months Ended

Sep. 30, 2022

Share-based payments [Abstract]

Weighted average fair value and exercise prices of options granted

The weighted average fair value and exercise prices of options granted is set out below.

	For the three months ended September 30,				For the nine months ended September 30,
	2022		2021		2022		2021
		$		$		$		$
Weighted average exercise price		37.25		39.02		25.49		26.19
Weighted average fair value		23.58		23.69		15.63		16.28

XML 33 R26.htm IDEA: XBRL DOCUMENT

Trade and other payables (Tables)

9 Months Ended

Sep. 30, 2022

Trade and other payables [Abstract]

Trade and other payables

	September 30, 2022 £’000		December 31, 2021 £’000
Trade payables		10,042		7,499
Other taxation and social security		1,423		532
Accruals		53,078		27,382
Other payables		385		23
		64,928		35,436

XML 34 R27.htm IDEA: XBRL DOCUMENT

Organization and nature of business (Details)		1 Months Ended		9 Months Ended
Organization and nature of business (Details)	Feb. 05, 2022 GBP (£)	Jul. 31, 2022 GBP (£) shares	Jul. 31, 2022 USD ($) shares	Sep. 30, 2022 ClinicalStageProgram
General information [Abstract]
Proceeds from shares issued		£ 116,812,000	$ 140,000,000
Offering expenses		£ 388,000
Number of clinical stage programs \| ClinicalStageProgram				5
Ordinary shares [member]
General information [Abstract]
Number of shares issued (in shares) \| shares		3,733,333	3,733,333
IPO [Member]
General information [Abstract]
Proceeds from shares issued	£ 210,985,000

XML 35 R28.htm IDEA: XBRL DOCUMENT

Significant accounting policies, Going concern (Details)	1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 31, 2022 GBP (£)	Jul. 31, 2022 USD ($)	Sep. 30, 2022 GBP (£)	Sep. 30, 2021 GBP (£)	Sep. 30, 2022 GBP (£)	Sep. 30, 2021 GBP (£)	Dec. 31, 2021 GBP (£)	Dec. 31, 2020 GBP (£)
Going concern [Abstract]
Cash and cash equivalents			£ 347,189,000	£ 256,551,000	£ 347,189,000	£ 256,551,000	£ 237,886,000	£ 129,716,000
Net current assets			326,303,000		326,303,000
Operating profit/(loss)			6,172,000	(30,950,000)	(17,281,000)	(97,330,000)
Net cash used in operating activities					(31,923,000)	(79,778,000)
Net product and net pre-product revenue			£ 36,303,000	£ 474,000	£ 74,514,000	£ 474,000
Proceeds from shares issued	£ 116,812,000	$ 140,000,000
Offering expenses	£ 388,000

XML 36 R29.htm IDEA: XBRL DOCUMENT

Significant accounting policies, Product revenue, net (Details)	9 Months Ended
	Sep. 30, 2022
Bottom of Range [Member]
Product revenue, net [Abstract]
Contractual payment terms	1 month
Top of Range [Member]
Product revenue, net [Abstract]
Contractual payment terms	2 months

XML 37 R30.htm IDEA: XBRL DOCUMENT

Significant accounting policies, Inventories (Details) £ in Thousands	9 Months Ended
	Sep. 30, 2022 GBP (£)
Inventories [Abstract]
Total Provision for reducing Inventories	£ 701
Inventory write down, amount	£ 185

XML 38 R31.htm IDEA: XBRL DOCUMENT

Revenue, Revenue recognised (Details) - GBP (£)	3 Months Ended		9 Months Ended
Revenue, Revenue recognised (Details) - GBP (£)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue recognitions [Abstract]
Product revenue, net	£ 33,252,000	£ 0	£ 64,926,000	£ 0
Pre-product revenue, net	3,051,000	474,000	9,588,000	474,000
Total revenue from sale of therapies	36,303,000	474,000	74,514,000	474,000
Collaboration revenue	4,896,000	5,450,000	21,161,000	19,453,000
Total revenue	41,199,000	5,924,000	95,675,000	19,927,000
United States [Member]
Revenue recognitions [Abstract]
Total revenue from sale of therapies	22,508,000	0	48,327,000	0
Europe [Member]
Revenue recognitions [Abstract]
Total revenue from sale of therapies	13,034,000	474,000	25,423,000	474,000
Rest of World [Member]
Revenue recognitions [Abstract]
Total revenue from sale of therapies	761,000	0	764,000	0
GSK [Member]
Revenue recognitions [Abstract]
Collaboration revenue	0	1,263,000	0	5,919,000
Eli Lilly [Member]
Revenue recognitions [Abstract]
Collaboration revenue	0	0	7,361,000	0
Genentech [Member]
Revenue recognitions [Abstract]
Collaboration revenue	£ 4,896,000	£ 4,187,000	£ 13,800,000	£ 13,534,000

XML 39 R32.htm IDEA: XBRL DOCUMENT

Revenue, Collaboration (Details) - GBP (£)	3 Months Ended			9 Months Ended
Revenue, Collaboration (Details) - GBP (£)	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Genentech [Member]
Collaboration [Abstract]
Revenue receivable for R&D word done	£ 624,000		£ 87,000	£ 984,000	£ 717,000
GSK [Member]
Collaboration [Abstract]
Revenue recognized		£ 0
Eli Lilly [Member]
Collaboration [Abstract]
Revenue recognized		£ 0

XML 40 R33.htm IDEA: XBRL DOCUMENT

Revenue, Deferred revenue (Details) - GBP (£)	3 Months Ended		9 Months Ended
Revenue, Deferred revenue (Details) - GBP (£)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Deferred revenue [Abstract]
Revenue recognized	£ 4,272,000		£ 20,177,000
Revenue recognised related to performance obligations	£ 0	£ 0	£ 0	£ 0

XML 41 R34.htm IDEA: XBRL DOCUMENT

Selling and Administrative Expenses (Details) - GBP (£)	3 Months Ended		9 Months Ended
Selling and Administrative Expenses (Details) - GBP (£)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Foreign exchange gain (loss) [abstract]
Foreign exchange gain	£ 15,184,000	£ 3,338,000	£ 24,343,000
Selling and Administrative Expense [Member]
Foreign exchange gain (loss) [abstract]
Foreign exchange gain				£ 1,080,000

XML 42 R35.htm IDEA: XBRL DOCUMENT

Finance costs (Details)		3 Months Ended				9 Months Ended
Finance costs (Details)	Nov. 08, 2022 USD ($) Tranche	Sep. 30, 2022 GBP (£)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 GBP (£)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 GBP (£)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 GBP (£)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 GBP (£)
Finance costs [Abstract]
Interest on lease liabilities (see Note 12)		£ 461,000		£ 428,000		£ 1,316,000		£ 1,301,000
Interest expenses on financial liabilities measured at amortized cost		1,324,000		889,000		3,199,000		3,164,000
Total finance costs		1,785,000		£ 1,317,000		4,515,000		4,465,000
Finance costs [Abstract]
Interest-bearing loans and borrowings		£ 45,563,000				45,563,000				£ 37,226,000
Oxford Debt Agreement [Member]
Finance costs [Abstract]
Interest expense on borrowings \| $			$ 50,000,000		$ 50,000,000		$ 50,000,000		$ 50,000,000
Interest expense								£ 546,000
Repayment of debt						1,579,000
Early repayment of finance fee						£ 225,000
Pharmakon loan agreement [Member] \| Subsequent events [Member]
Finance costs [Abstract]
Borrowings, maximum capacity \| $	$ 100,000,000
Number of traches associated to borrow agreement \| Tranche	2
Pharmakon Loan Agreement, Tranche One [Member] \| Subsequent events [Member]
Finance costs [Abstract]
Borrowings, maximum capacity \| $	$ 50,000,000
Fixed interest rate	9.75%
Maturity period of draw	6 years
IPO [Member] \| Oxford Debt Agreement [Member]
Finance costs [Abstract]
Interest expense \| $							$ 750,000

XML 43 R36.htm IDEA: XBRL DOCUMENT

Income tax (Details) - GBP (£)	9 Months Ended
Income tax (Details) - GBP (£)	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Tax rate [Abstract]
Effective tax credit rate	24.00%	9.50%
Deferred tax asset	£ 3,860,000		£ 2,575,000
Unused tax credits [Member]
Tax rate [Abstract]
Deferred tax asset	3,860,000		£ 2,575,000
UK [Member]
Tax rate [Abstract]
Research and development tax credit	£ 5,050,000

XML 44 R37.htm IDEA: XBRL DOCUMENT

Basic and diluted profit / (loss) per share (Details) - GBP (£)
£ / shares in Units, £ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Basic and diluted profit/ (loss) [Abstract]

Profit / (loss) for the period

£ 6,228

£ (30,134)

£ (16,021)

£ (92,134)

Basic weighted average number of shares (in shares)

46,998,420

43,796,084

44,944,827

42,030,746

Adjustment for stock options with dilutive effect (in shares)

4,444,856

Diluted weighted average number of shares (in shares)

51,443,276

43,796,084

44,944,827

42,030,746

Basic earnings / (loss) per share (in pounds per share)

^[1]

£ 0.13

£ (0.69)

£ (0.36)

£ (2.19)

Diluted earnings / (loss) per share (in pounds per share)

^[1]

£ 0.12

£ (0.69)

£ (0.36)

£ (2.19)

Antidilutive securities [Abstract]

Antidilutive securities excluded from calculation of diluted weighted average number of shares outstanding (in shares)

88,695

[1]

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

+ Details

XML 45 R38.htm IDEA: XBRL DOCUMENT

Trade and other receivables (Details) - GBP (£) £ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Trade and other receivables [Abstract]
Trade receivables	£ 25,809	£ 6,047
Other receivables	6,214	1,470
Prepayments and accrued income	8,945	7,691
Total trade and other receivables	£ 40,968	£ 15,208

XML 46 R39.htm IDEA: XBRL DOCUMENT

Leases, (Details) - GBP (£)	Sep. 30, 2022	Jul. 13, 2022	Dec. 31, 2021
Leases [Abstract]
Lease liabilities	£ 2,472,000	£ 5,483,000
Contingent liability			£ 1,122,000
Initial right-of-use asset	£ 2,472,000

XML 47 R40.htm IDEA: XBRL DOCUMENT

Capital and reserves, Shares Issued (Details)	1 Months Ended			9 Months Ended
Capital and reserves, Shares Issued (Details)	Jul. 31, 2022 GBP (£) £ / shares shares	Jul. 31, 2022 USD ($)	Apr. 30, 2022 GBP (£) shares	Sep. 30, 2022 GBP (£)	Jul. 31, 2022 $ / shares shares
Issued share [Abstract]
Reduction of capital amount \| £				£ 0
Gross proceeds	£ 116,812,000	$ 140,000,000
Offering expenses \| £	388,000
Retained earnings [member]
Issued share [Abstract]
Reduction of capital amount \| £			£ 261,400,000	£ (261,363,000)
Investors [Member]
Issued share [Abstract]
Gross proceeds	116,812,000	$ 140,000,000
Offering expenses \| £	£ 388,000
Ordinary Shares [Member]
Issued share [Abstract]
Shares cancelled (in shares)			23,702,856,974
Number of shares issued (in shares)	3,733,333				3,733,333
Ordinary Shares [Member] \| Investors [Member]
Issued share [Abstract]
Share price (in dollars per share) \| $ / shares					$ 37.5
ADS [Member]
Issued share [Abstract]
Number of shares issued (in shares)	2,000,000				2,000,000
Par value per share (in pounds per share) \| £ / shares	£ 0.002
Non-voting Ordinary Shares [Member]
Issued share [Abstract]
Shares cancelled (in shares)			457,338,326
Number of shares issued (in shares)	1,733,333				1,733,333
Par value per share (in pounds per share) \| £ / shares	£ 0.002

XML 48 R41.htm IDEA: XBRL DOCUMENT

Capital and reserves, Issued share capital (Details)	9 Months Ended
Capital and reserves, Issued share capital (Details)	Sep. 30, 2022 shares
Ordinary Shares [Member]
Issued and Fully Paid Share Capital [Abstract]
Number of shares outstanding at beginning of period (in shares)	43,862,850
New shares issued for cash (in shares)	3,733,333
Exercise of share options (in shares)	308,776
Number of shares outstanding at end of period (in shares)	47,904,959
Deferred Shares [Member]
Issued and Fully Paid Share Capital [Abstract]
Number of shares outstanding at beginning of period (in shares)	5,793,501
New shares issued for cash (in shares)	0
Exercise of share options (in shares)	0
Number of shares outstanding at end of period (in shares)	5,793,501

XML 49 R42.htm IDEA: XBRL DOCUMENT

Share-based payments (Details) £ in Thousands	3 Months Ended				9 Months Ended
Share-based payments (Details) £ in Thousands	Sep. 30, 2022 GBP (£) shares	Sep. 30, 2022 shares $ / shares	Sep. 30, 2021 GBP (£) shares	Sep. 30, 2021 shares $ / shares	Sep. 30, 2022 GBP (£) shares	Sep. 30, 2022 shares $ / shares	Sep. 30, 2021 GBP (£) shares	Sep. 30, 2021 shares $ / shares
Share-based payments awards [Abstract]
Share-based payment charge \| £	£ 6,093		£ 9,200		£ 20,181		£ 27,138
Awards granted, number of share options (in shares)	2,100		4,000		1,365,753		4,538,527
Share-based compensation arrangement by award vesting period					4 years
Share-based compensation arrangement by award vesting percentage					0.25
Vesting period					3 years
Weighted average fair value and exercise prices of options granted [Abstract]
Weighted average exercise price (in dollars per share) \| $ / shares		$ 37.25		$ 39.02		$ 25.49		$ 26.19
Weighted average fair value \| $ / shares		$ 23.58		$ 23.69		$ 15.63		$ 16.28
Number of share options outstanding (in shares)	9,942,203	9,942,203	9,199,742	9,199,742	9,942,203	9,942,203	9,199,742	9,199,742
Number of share options exercisable (in shares)	4,661,406	4,661,406	2,506,791	2,506,791	4,661,406	4,661,406	2,506,791	2,506,791
Non-Executive Directors [Member]
Share-based payments awards [Abstract]
Awards granted, number of share options (in shares)					66,972
Share-based compensation arrangement by award vesting period					1 year

XML 50 R43.htm IDEA: XBRL DOCUMENT

Trade and other payables (Details) - GBP (£) £ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Trade and other payables [Abstract]
Trade payables	£ 10,042	£ 7,499
Other taxation and social security	1,423	532
Accruals	53,078	27,382
Other payables	385	23
Trade and other payables	£ 64,928	£ 35,436

XML 51 R44.htm IDEA: XBRL DOCUMENT

Events after the reporting period (Details) - Subsequent Events [Member] $ in Millions	Nov. 08, 2022 USD ($) Loan Tranche	Nov. 07, 2022 USD ($)
Medison Pharma Ltd [Member]
Events After the Reporting Periods [Abstract]
Expected receivable non-refundable upfront fee		$ 5
Pharmakon Loan Agreement [Member]
Events After the Reporting Periods [Abstract]
Borrowings, maximum capacity	$ 100
Number of tranches \| Tranche	2
Pharmakon Loan Agreement, Tranche One [Member]
Events After the Reporting Periods [Abstract]
Borrowings, maximum capacity	$ 50
Fixed interest rate	9.75%
Maturity period of term loan	6 years
Pharmakon Loan Agreement, Tranche Two [Member]
Events After the Reporting Periods [Abstract]
Borrowings, maximum capacity	$ 50
Borrowings, minimum draw capacity	$ 25
Pharmakon Loan Agreement, Tranche Two [Member] \| Bottom of Range [Member]
Events After the Reporting Periods [Abstract]
Number of term loans \| Loan	1
Pharmakon Loan Agreement, Tranche Two [Member] \| Top of Range [Member]
Events After the Reporting Periods [Abstract]
Number of term loans \| Loan	2
Oxford Finance Agreement [Member]
Events After the Reporting Periods [Abstract]
Repayment of debt	$ 50

XML 52 brhc10044110_ex99-1_htm.xml IDEA: XBRL DOCUMENT 0001671927 2022-01-01 2022-09-30 0001671927 2021-01-01 2021-09-30 0001671927 2021-07-01 2021-09-30 0001671927 2022-07-01 2022-09-30 0001671927 2021-12-31 0001671927 2022-09-30 0001671927 ifrs-full:ReserveOfCashFlowHedgesMember 2020-12-31 0001671927 ifrs-full:RetainedEarningsMember 2021-12-31 0001671927 ifrs-full:SharePremiumMember 2021-12-31 0001671927 ifrs-full:IssuedCapitalMember 2020-12-31 0001671927 2020-12-31 0001671927 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001671927 ifrs-full:RetainedEarningsMember 2020-12-31 0001671927 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-12-31 0001671927 ifrs-full:ReserveOfSharebasedPaymentsMember 2020-12-31 0001671927 ifrs-full:SharePremiumMember 2020-12-31 0001671927 ifrs-full:IssuedCapitalMember 2021-12-31 0001671927 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001671927 ifrs-full:ReserveOfCashFlowHedgesMember 2021-12-31 0001671927 ifrs-full:SharePremiumMember 2022-01-01 2022-09-30 0001671927 ifrs-full:ReserveOfCashFlowHedgesMember 2022-01-01 2022-09-30 0001671927 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-01-01 2022-09-30 0001671927 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-01-01 2022-09-30 0001671927 ifrs-full:SharePremiumMember 2021-01-01 2021-09-30 0001671927 ifrs-full:ReserveOfCashFlowHedgesMember 2021-01-01 2021-09-30 0001671927 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-01-01 2021-09-30 0001671927 ifrs-full:RetainedEarningsMember 2022-01-01 2022-09-30 0001671927 ifrs-full:RetainedEarningsMember 2021-01-01 2021-09-30 0001671927 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-09-30 0001671927 ifrs-full:IssuedCapitalMember 2022-01-01 2022-09-30 0001671927 ifrs-full:IssuedCapitalMember 2021-01-01 2021-09-30 0001671927 ifrs-full:RetainedEarningsMember 2022-09-30 0001671927 ifrs-full:ReserveOfSharebasedPaymentsMember 2022-09-30 0001671927 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-09-30 0001671927 2021-09-30 0001671927 ifrs-full:ReserveOfCashFlowHedgesMember 2021-09-30 0001671927 ifrs-full:SharePremiumMember 2021-09-30 0001671927 ifrs-full:IssuedCapitalMember 2021-09-30 0001671927 ifrs-full:ReserveOfCashFlowHedgesMember 2022-09-30 0001671927 ifrs-full:ReserveOfSharebasedPaymentsMember 2021-09-30 0001671927 ifrs-full:RetainedEarningsMember 2021-09-30 0001671927 ifrs-full:SharePremiumMember 2022-09-30 0001671927 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2022-09-30 0001671927 ifrs-full:IssuedCapitalMember 2022-09-30 0001671927 imcr:InitialPublicOfferingMember 2022-02-05 2022-02-05 0001671927 2022-07-01 2022-07-31 0001671927 ifrs-full:OrdinarySharesMember 2022-07-31 0001671927 ifrs-full:BottomOfRangeMember 2022-01-01 2022-09-30 0001671927 ifrs-full:TopOfRangeMember 2022-01-01 2022-09-30 0001671927 imcr:RestOfWorldMember 2022-07-01 2022-09-30 0001671927 currency:XBC 2021-01-01 2021-09-30 0001671927 currency:XBC 2021-07-01 2021-09-30 0001671927 currency:XBC 2022-01-01 2022-09-30 0001671927 country:US 2022-07-01 2022-09-30 0001671927 imcr:RestOfWorldMember 2021-07-01 2021-09-30 0001671927 currency:XBC 2022-07-01 2022-09-30 0001671927 imcr:RestOfWorldMember 2021-01-01 2021-09-30 0001671927 country:US 2022-01-01 2022-09-30 0001671927 country:US 2021-01-01 2021-09-30 0001671927 country:US 2021-07-01 2021-09-30 0001671927 imcr:RestOfWorldMember 2022-01-01 2022-09-30 0001671927 imcr:EliLillyMember 2022-07-01 2022-09-30 0001671927 imcr:GlaxoSmithKlineMember 2022-01-01 2022-09-30 0001671927 imcr:GenentechMember 2022-07-01 2022-09-30 0001671927 imcr:EliLillyMember 2021-01-01 2021-09-30 0001671927 imcr:GlaxoSmithKlineMember 2021-07-01 2021-09-30 0001671927 imcr:EliLillyMember 2022-01-01 2022-09-30 0001671927 imcr:EliLillyMember 2021-07-01 2021-09-30 0001671927 imcr:GenentechMember 2021-07-01 2021-09-30 0001671927 imcr:GlaxoSmithKlineMember 2021-01-01 2021-09-30 0001671927 imcr:GenentechMember 2022-01-01 2022-09-30 0001671927 imcr:GlaxoSmithKlineMember 2022-07-01 2022-09-30 0001671927 imcr:GenentechMember 2021-01-01 2021-09-30 0001671927 imcr:GlaxoSmithKlineMember 2022-01-01 2022-03-31 0001671927 imcr:EliLillyMember 2022-01-01 2022-03-31 0001671927 ifrs-full:SellingGeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001671927 imcr:OxfordDebtAgreementMember 2022-07-01 2022-09-30 0001671927 imcr:OxfordDebtAgreementMember 2021-01-01 2021-09-30 0001671927 imcr:OxfordDebtAgreementMember 2022-01-01 2022-09-30 0001671927 imcr:OxfordDebtAgreementMember 2021-07-01 2021-09-30 0001671927 imcr:OxfordDebtAgreementMember imcr:InitialPublicOfferingMember 2022-01-01 2022-09-30 0001671927 imcr:PharmakonLoanAgreementMember imcr:SubsequentEventsMember 2022-11-08 0001671927 imcr:PharmakonLoanAgreementTrancheOneMember imcr:SubsequentEventsMember 2022-11-08 0001671927 imcr:PharmakonLoanAgreementTrancheOneMember imcr:SubsequentEventsMember 2022-11-08 2022-11-08 0001671927 country:GB 2022-01-01 2022-09-30 0001671927 ifrs-full:UnusedTaxCreditsMember 2021-12-31 0001671927 ifrs-full:UnusedTaxCreditsMember 2022-09-30 0001671927 2022-07-13 0001671927 ifrs-full:OrdinarySharesMember 2022-04-01 2022-04-30 0001671927 imcr:NonVotingOrdinarySharesMember 2022-04-01 2022-04-30 0001671927 ifrs-full:RetainedEarningsMember 2022-04-01 2022-04-30 0001671927 imcr:AmericanDepositarySharesMember 2022-07-31 0001671927 imcr:NonVotingOrdinarySharesMember 2022-07-31 0001671927 imcr:InvestorsMember ifrs-full:OrdinarySharesMember 2022-07-31 0001671927 imcr:InvestorsMember 2022-07-01 2022-07-31 0001671927 ifrs-full:OrdinarySharesMember 2021-12-31 0001671927 imcr:DeferredSharesMember 2021-12-31 0001671927 imcr:DeferredSharesMember 2022-01-01 2022-09-30 0001671927 ifrs-full:OrdinarySharesMember 2022-01-01 2022-09-30 0001671927 imcr:DeferredSharesMember 2022-09-30 0001671927 ifrs-full:OrdinarySharesMember 2022-09-30 0001671927 imcr:NonExecutiveDirectorsMember 2022-01-01 2022-09-30 0001671927 imcr:PharmakonLoanAgreementTrancheTwoMember imcr:SubsequentEventsMember 2022-11-08 0001671927 imcr:OxfordFinanceAgreementMember imcr:SubsequentEventsMember 2022-11-08 2022-11-08 0001671927 imcr:PharmakonLoanAgreementTrancheTwoMember imcr:SubsequentEventsMember ifrs-full:TopOfRangeMember 2022-11-08 2022-11-08 0001671927 imcr:PharmakonLoanAgreementTrancheTwoMember imcr:SubsequentEventsMember ifrs-full:BottomOfRangeMember 2022-11-08 2022-11-08 0001671927 imcr:MedisonPharmaLtdMember imcr:SubsequentEventsMember 2022-11-07 iso4217:GBP iso4217:GBP shares iso4217:USD shares imcr:ClinicalStageProgram imcr:Tranche pure iso4217:USD shares imcr:Loan 6-K/A false 2022-09-30 --12-31 Immunocore Holdings plc 0001671927 P1M 0 0 0 0 0 33252000 0 64926000 0 3051000 474000 9588000 474000

36303000

474000

74514000

474000

4896000 5450000 21161000 19453000

41199000

5924000

95675000

19927000

63000

345000

23301000

16798000

62032000

53154000

11663000

20048000

50580000

64033000

0 -28000 1000 -70000

6172000

-30950000

-17281000

-97330000

597000

8000

725000

42000

1785000

1317000

4515000

4465000

-1188000

-1309000

-3790000

-4423000

4984000

-32259000

-21071000

-101753000

-1244000

-2125000

-5050000

-9619000

6228000

-30134000

-16021000

-92134000

-1730000

-38000

-1848000

-92000

-1730000

-38000

-1848000

-92000

4498000

-30172000

-17869000

-92226000

0.13

-0.69

-0.36

-2.19

0.12

-0.69

-0.36

-2.19

6580000

8944000

23963000

22593000

6749000

4935000

3860000

2575000

41152000

39047000

854000

40968000

15208000

14510000

9632000

347189000

237886000

403521000

262726000

444673000

301773000

96000

88000

120147000

212238000

-1759000

89000

337847000

386167000

74538000

54357000

-236050000

-481392000

294819000

171547000

45563000

37226000

6408000

26965000

25355000

108000

57000

72636000

69046000

64928000

35436000

10681000

24450000

1553000

1255000

56000

39000

77218000

61180000

149854000

130226000

444673000

301773000

88000

212238000

89000

54357000

386167000

-481392000

171547000

-16021000

-1848000

-16021000

-17869000

1000 4535000 0 0 0 0 4536000 0 213043000 0 0 48320000 -261363000 0

7000

116417000

116424000

20181000

96000

120147000

-1759000

74538000

337847000

-236050000

294819000

64000

163000

18821000

386167000

-349869000

55346000

-92134000

-92000

-92134000

-92226000

24000

210961000

210985000

0 644000 0 0 0 0 644000

325000

26813000

27138000

88000

211930000

71000

45634000

386167000

-442003000

201887000

-16021000

-92134000

20181000

27138000

4794000

5294000

-3790000

-4423000

-20498000

320000

-1000

273000

-5050000

-9619000

-25021000

-1684000

27501000

3085000

-20177000 -16853000

-807000

-21000

-31309000

-79778000

-614000

-31923000

-79778000

5000

64000

869000

730000

549000

725000

15000

-139000

-102000

116812000

226528000

388000

15543000

4536000

644000

3050000

2473000

2265000

2465000

115645000

206691000

83583000

126811000

25720000

24000

237886000

129716000

347189000

256551000

<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">1. Organization and nature of business</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">General information</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Immunocore Holdings plc (the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries: Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited (collectively referred to as the “Group”).</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company’s American Depositary Shares (“ADSs”) began trading on the Nasdaq Global Select Market under the ticker symbol “IMCR” on February 5, 2021, following its initial public offering (“IPO”). The IPO and concurrent private placement generated net proceeds of £210,985,000 after underwriting discounts, commissions and directly attributable offering expenses. In July 2022, the Company issued and sold a total of 3,733,333 ordinary shares to certain institutional accredited investors as a private investment in public entity (the “PIPE”) pursuant to a securities purchase agreement, generating proceeds of £116,812,000 ($140,000,000) before deductions for offering expenses of £388,000.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The principal activity of the Group is pioneering the development and sale of a novel class of TCR bispecific immunotherapies called ImmTAX – <span style="font-weight: bold;"><span style="text-decoration: underline;">I</span></span>mmune <span style="font-weight: bold;"><span style="text-decoration: underline;">m</span></span>obilizing <span style="font-weight: bold;"><span style="text-decoration: underline;">m</span></span>onoclonal <span style="font-weight: bold;"><span style="text-decoration: underline;">T</span></span>CRs <span style="font-weight: bold;"><span style="text-decoration: underline;">A</span></span>gainst <span style="font-weight: bold;"><span style="text-decoration: underline;">X</span></span> disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, the Group is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In January and April 2022, the Group received approval from the U.S. Food and Drug Administration (“FDA”) and European Commission (“EC”), respectively, for its lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma (“mUM”). In June 2022, the UK’s MHRA, Health Canada, and the Australian Government Department of Health’s TGA have each approved KIMMTRAK for the treatment of HLA-A*02:01-positive adult patients with unresectable or mUM. KIMMTRAK is now approved in over 30 countries with commercial launches underway in the U.S., Germany, France and Canada. The Group expects to obtain regulatory approval for KIMMTRAK in further territories in the next year.</div>

210985000

3733333

116812000

140000000

388000

<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2. Significant accounting policies</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Basis of preparation</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with International Accounting Standard 34, “<span style="font-style: italic;">Interim Financial Reporting”</span> (“IAS 34”). Except as described in Significant Accounting Policies below, the accounting policies applied in these interim financial statements are the same as those applied in the Group’s consolidated financial statements as at and for the year ended December 31, 2021.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed consolidated interim financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Group for the year ended December 31, 2021 included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 3, 2022 (the “Annual Report”). New accounting policies applicable to the three and nine months ended September 30, 2022, are outlined further below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed and consolidated interim financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in pounds sterling which is the Company’s functional currency. All values are rounded to the nearest thousand, except where otherwise indicated.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Date of authorization</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">These unaudited condensed consolidated interim financial statements were prepared at the request of the Company’s Board of Directors (the “Board”) and were approved by the Board on November 9, 2022, and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer of the Group.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Adoption of new accounting standards</div> <div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">There have been no new accounting standards adopted by the Group in 2022 which have had a material impact on these unaudited condensed consolidated interim financial statements. There are no standards issued but not yet effective that the Group expects to have a material impact on its financial statements.</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Going concern</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Group reported cash and cash equivalents of £347,189,000 and net current assets of £326,303,000 as at September 30, 2022, with an operating profit / (loss) for the three and nine months ended September 30, 2022 of £6,172,000 and (£17,281,000), respectively, and net cash used in operating activities for the nine months ended September 30, 2022 of £31,923,000. The negative operational cash flow was largely due to the Group’s continued focus on research, development, and clinical activities to advance preclinical and clinical programs within the Group’s pipeline. The Group generated net product and net pre-product revenue totalling £36,303,000 and £74,514,000 during the three and nine months ended September 30, 2022, respectively. In July 2022, the Group received £116,812,000 ($140,000,000) before deduction of attributable expenses of £388,000 following the PIPE.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In assessing the going concern assumptions, the Board has undertaken an assessment of the current business and strategy forecasts covering a two-year period, which includes anticipated KIMMTRAK revenue. In assessing the downside risks, the Board has also considered scenarios incorporating a range of revenue arising from KIMMTRAK sales. As part of considering the downside risks, the Board has considered the impact of the ongoing coronavirus 2019 (‘‘COVID-19’’) pandemic and other potential economic impacts including the war in Ukraine and related geopolitical tensions, as well as global inflation, capital market instability, exchange rate fluctuations, and increases in commodity, energy and fuel prices. The Board has concluded that while these may have a future impact on the Group’s business and implementation of its strategy and plans, it anticipates that any such impact will be minimal on clinical trials or other business activities over the period assessed for going concern purposes. As of the date of these financial statements, the Group is not aware of any specific event or circumstance that would require the Group to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Group’s financial statements.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">Given the current cash position and the assessment performed, the Board believes that the Group will have sufficient funds to continue to meet its liabilities as they fall due throughout the forecast period outlined above and therefore, the Group has prepared the financial statements on a going concern basis. </span>This scenario is based on the Group’s lower range of anticipated revenue levels. <span style="color: rgb(0, 0, 0);">As the Group continues to incur significant expenses in the pursuit of its business strategy, including further commercialization and marketing plans for KIMMTRAK, additional funding will be needed before further existing clinical and preclinical programs may be expected to reach commercialization, which would potentially lead to </span>additional<span style="color: rgb(0, 0, 0);"> operational cash inflows. Until the Group can generate revenue from product sales sufficient to fund its ongoing operations and further develop its pipeline, if ever, it expects to finance its operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements.</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Estimates and judgements</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as contingent liabilities and income and expenses in the financial period. The estimates and associated assumptions are based on information available when the unaudited condensed consolidated interim financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to market changes or circumstances arising that are beyond the Group’s control. Therefore, estimates may vary from eventual outcomes and may be subject to updates in future reported periods.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Judgements and estimates made, together with our significant accounting policies, are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2021, and are presented in the Group’s Annual Report. Significant updates to the Group’s estimates and accounting policies for the three and nine months ended September 30, 2022 are outlined below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Critical Accounting Estimates</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Estimated rebates, chargebacks and product returns</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As outlined below in the “Product revenue, net” policy, the Group recognizes revenue net of estimated deductions for rebates, chargebacks, other customer fees and product returns.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Due to its limited history of product sales in the United States having only recently received regulatory approval for its first product, the Group has limited directly comparable information of actual rebate claims, chargebacks or levels of product returns, and the Group’s early sales information may have limited predictive value. The Group uses the expected value method to estimate revenue deductions, which considers the likelihood of a rebate, chargeback or product return being applicable to sales. The proportion of sales subject to a rebate or chargeback, and the level of product returns, is inherently uncertain and the Group’s estimates are based on internal assumptions, which may change as the Group develops more product experience, and third-party data, which the Group assesses for reliability and relevance.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Rebates and chargebacks</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">The Group is subject to state government Medicaid programs and other qualifying federal and state programs in the United States requiring rebates to be paid to participating state and local government entities, depending on the eligibility and circumstances of patients treated with KIMMTRAK after the Group has sold vials to specialty distributors. The Group is also subject to chargebacks from its specialty distributors under the 340B program in the United States, whereby qualifying hospitals are entitled to purchase KIMMTRAK at a lower price. For such sales, the Group’s specialty distributors charge back the difference between the wholesale acquisition cost and this lower price. Estimating rebate and chargeback deductions from revenue is judgmental due to the time delay between the date of the sale to specialty distributors and the subsequent dates on which the Group is able to determine actual amounts of chargebacks and rebates. The Group forms estimates of 340B chargeback deductions by</span> <span style="color: rgb(0, 0, 0);">analyzing sell-through data relating to the hospital mix of onward sales made by specialty distributors. For Medicaid and other rebates, </span>the Group forms estimates based on internal forecasts of the patient mix and external health coverage statistics<span style="color: rgb(0, 0, 0);">. Judgment is applied to consider the relevance and reliability of information used to make these estimates.</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Judgment is also required in determining the amount of the Group’s net pre-product revenue and product revenue in France. Rebates payable to the Economic Committee for Health Products (“CEPS”) under compassionate use, early access and commercial programs are subject to a high degree of estimation uncertainty. The Group’s estimate of these rebates represents the difference between the expected agreed price for the commercial sale of KIMMTRAK in France, which is subject to price negotiation, and the initial price of tebentafusp and KIMMTRAK sold under early access and commercial programs until this price is agreed. Analysis of further legislative requirements, sales volumes and the expected benefit of KIMMTRAK to patients in France is also required in the assessment of rebates payable. The Group applies judgement to assess internal targets, pricing information of other therapies approved for sale in France, information obtained from price negotiations of KIMMTRAK in other countries, and information connected with KIMMTRAK’s safety profile when forming its estimated rebate deduction from revenue.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Product returns</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Group considers several inputs when estimating potential levels of product returns. Due to the nature of KIMMTRAK as a therapy, the Group expects no product returns following patient administration by trained healthcare professionals. The Group applies judgement in assessing the level of returns for sales made to distributors which have yet to be administered to patients. The Group considers industry average return levels, distributor sell-through rates, the levels of inventory in the distribution channel, the period of time for which inventory has been held by its distributors, the level of orders placed, the expiry date of products sold, and its distributors’ right to return products in the case of vials of KIMMTRAK with a shorter period to expiry. As orders are typically placed based on scheduled administration by hospitals and healthcare facilities, the Group does not expect a significant level of product returns.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Significant Accounting Policies</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Product revenue, net</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Product revenue, net, relates to the sale of KIMMTRAK following marketing approval. The Group recognizes revenue at the point in time that control transfers to a customer, which is typically on delivery. The Group also operates under consignment arrangements where control passes when the Group’s distributor takes KIMMTRAK out of consignment inventory. The amount of revenue recognized under its arrangements reflects the consideration to which the Group expects to be entitled to, net of estimated deductions for rebates, chargebacks, other customer fees and product returns. Estimated revenue deductions are updated at the end of each reporting period using the latest available data. The Group considers whether any part of amounts expected to be received should be constrained to ensure that it is highly probable that a significant reversal in the cumulative revenue recognized will not occur. Estimating such deductions involves judgments which are detailed further above under “Critical accounting estimates”.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Group’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list prices with standard payment terms typically between <span style="-sec-ix-hidden:Fact_7deac9cd51f749f0b91f64d454f0639d">one</span> and two months. When the Group has the right to offset chargebacks against trade receivables and the parties have agreed to settle the payments net, chargebacks are recorded as a reduction in trade receivables. Other chargebacks, rebates and deductions are recognized as an accrual in the condensed consolidated statement of financial position.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; font-family: 'Times New Roman'; font-size: 10pt;">The Group’s customers are hospitals and healthcare providers in certain countries, where KIMMTRAK is sold through an agent acting on the Group’s behalf.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Pre-product revenue, net</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-product revenue, net, relates to the sale of tebentafusp under a compassionate use and an early access program in France up to September 2022. These programs provided patients with access to tebentafusp before KIMMTRAK became available as a marketed product in France. Pre-product revenue is recognized on delivery of tebentafusp to healthcare providers, which is the point in time when control is transferred. Such revenue is recognized net and represents the prices set by the Group that are expected to be retained after estimated deductions and to the extent that it is highly probable that a significant reversal of revenue will not occur. These variable estimated deductions include both an estimate of government rebates payable and an estimate of returns in the case of expiry, damage or other instances. The total rebate payable by the Group is dependent on the outcome of price negotiations with the French government, and the Group makes an estimate of these amounts payable each reporting period based on available pricing information and the applicable regulations. Returns are estimated based on industry trends and information provided by the Group’s distributors.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The estimates for rebates and returns deducted from pre-product revenue are recorded in the period the related pre-product revenue is recognized and are classified under Accruals within Trade and other payables in the Condensed Consolidated Statement of Financial Position. Costs of pre-product revenue are expensed when incurred and include costs associated with previous manufacturing of tebentafusp and other third-party selling expenses. Previous manufacturing costs were recognized in Research and development expenses at the time, and third-party selling expenses are recognized within Selling and administrative expenses.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenue</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenue represents production costs including raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale. Due to the Group’s manufacturing arrangements, overheads and internal costs of product revenue are minimal. Further information on Cost of product revenue is included within the ‘Inventories’ policy below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Trade Receivables</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Trade receivables include amounts invoiced or contractually accrued where only the passage of time is required before payment is received under the Group’s collaboration agreements and other revenue arrangements. Trade receivables are assessed for impairment using the simplified approach under IFRS 9, <span style="font-style: italic;">Financial Instruments</span>, which requires lifetime expected losses to be recognized with the initial recognition of the receivable. Due to its lack of sales history, the Group estimates expected credit losses using internal information, industry credit default information, and comparable information available from companies with similar customers. As of September 30, 2022, the amount of expected credit losses is not material.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Inventories</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Inventories include finished goods manufactured for commercial sale, items in the process of being manufactured for commercial sale, and the materials to be used in the manufacturing process. The principal costs in manufacturing the Group’s inventories are raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Inventories are measured at weighted average cost and presented as assets in the Condensed Consolidated Statement of Financial Position to the extent that they are recoverable. Inventories are stated at the lower of cost and net realizable value, and the Group assesses whether an expense should be recognized to write down inventory values at each reporting period. Where this expense relates to inventories manufactured or developed following marketing approval of KIMMTRAK, the Group recognizes the expense within Cost of product revenue. Prior to receiving marketing approval, the Group recorded the expense for prelaunch inventory expected to be sold in the ordinary course of business within Research and development expenses. Reversals of previous write-downs of inventories are recognized within Cost of product revenue or Research and development expenses, depending on where the write-down was originally recognized.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As at September 30, 2022, the Group held a provision against the value of its inventories of £701,000, of which £185,000 has been recognized in Cost of product revenue in the Condensed Consolidated Statement of Profit / (Loss) and Comprehensive Loss in the nine months ended September 30, 2022.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Due to the low costs involved in manufacturing KIMMTRAK, inventory costs and Cost of product revenue are not material at this time, and the Group does not expect these costs to be material for the foreseeable future.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Basis of preparation</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with International Accounting Standard 34, “<span style="font-style: italic;">Interim Financial Reporting”</span> (“IAS 34”). Except as described in Significant Accounting Policies below, the accounting policies applied in these interim financial statements are the same as those applied in the Group’s consolidated financial statements as at and for the year ended December 31, 2021.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed consolidated interim financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the annual consolidated financial statements of the Group for the year ended December 31, 2021 included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 3, 2022 (the “Annual Report”). New accounting policies applicable to the three and nine months ended September 30, 2022, are outlined further below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The unaudited condensed and consolidated interim financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in pounds sterling which is the Company’s functional currency. All values are rounded to the nearest thousand, except where otherwise indicated.</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Date of authorization</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">These unaudited condensed consolidated interim financial statements were prepared at the request of the Company’s Board of Directors (the “Board”) and were approved by the Board on November 9, 2022, and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer of the Group.</div> <div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Adoption of new accounting standards</div> <div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">There have been no new accounting standards adopted by the Group in 2022 which have had a material impact on these unaudited condensed consolidated interim financial statements. There are no standards issued but not yet effective that the Group expects to have a material impact on its financial statements.</span></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Going concern</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Group reported cash and cash equivalents of £347,189,000 and net current assets of £326,303,000 as at September 30, 2022, with an operating profit / (loss) for the three and nine months ended September 30, 2022 of £6,172,000 and (£17,281,000), respectively, and net cash used in operating activities for the nine months ended September 30, 2022 of £31,923,000. The negative operational cash flow was largely due to the Group’s continued focus on research, development, and clinical activities to advance preclinical and clinical programs within the Group’s pipeline. The Group generated net product and net pre-product revenue totalling £36,303,000 and £74,514,000 during the three and nine months ended September 30, 2022, respectively. In July 2022, the Group received £116,812,000 ($140,000,000) before deduction of attributable expenses of £388,000 following the PIPE.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In assessing the going concern assumptions, the Board has undertaken an assessment of the current business and strategy forecasts covering a two-year period, which includes anticipated KIMMTRAK revenue. In assessing the downside risks, the Board has also considered scenarios incorporating a range of revenue arising from KIMMTRAK sales. As part of considering the downside risks, the Board has considered the impact of the ongoing coronavirus 2019 (‘‘COVID-19’’) pandemic and other potential economic impacts including the war in Ukraine and related geopolitical tensions, as well as global inflation, capital market instability, exchange rate fluctuations, and increases in commodity, energy and fuel prices. The Board has concluded that while these may have a future impact on the Group’s business and implementation of its strategy and plans, it anticipates that any such impact will be minimal on clinical trials or other business activities over the period assessed for going concern purposes. As of the date of these financial statements, the Group is not aware of any specific event or circumstance that would require the Group to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from these estimates, and any such differences may be material to the Group’s financial statements.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">Given the current cash position and the assessment performed, the Board believes that the Group will have sufficient funds to continue to meet its liabilities as they fall due throughout the forecast period outlined above and therefore, the Group has prepared the financial statements on a going concern basis. </span>This scenario is based on the Group’s lower range of anticipated revenue levels. <span style="color: rgb(0, 0, 0);">As the Group continues to incur significant expenses in the pursuit of its business strategy, including further commercialization and marketing plans for KIMMTRAK, additional funding will be needed before further existing clinical and preclinical programs may be expected to reach commercialization, which would potentially lead to </span>additional<span style="color: rgb(0, 0, 0);"> operational cash inflows. Until the Group can generate revenue from product sales sufficient to fund its ongoing operations and further develop its pipeline, if ever, it expects to finance its operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements.</span></div>

347189000

326303000

6172000

-17281000

-31923000

36303000

74514000

116812000

140000000

388000

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Estimates and judgements</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as contingent liabilities and income and expenses in the financial period. The estimates and associated assumptions are based on information available when the unaudited condensed consolidated interim financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances. Existing circumstances and assumptions about future developments may change due to market changes or circumstances arising that are beyond the Group’s control. Therefore, estimates may vary from eventual outcomes and may be subject to updates in future reported periods.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Judgements and estimates made, together with our significant accounting policies, are disclosed in the consolidated financial statements of the Group for the year ended December 31, 2021, and are presented in the Group’s Annual Report. Significant updates to the Group’s estimates and accounting policies for the three and nine months ended September 30, 2022 are outlined below.</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Critical Accounting Estimates</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Estimated rebates, chargebacks and product returns</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As outlined below in the “Product revenue, net” policy, the Group recognizes revenue net of estimated deductions for rebates, chargebacks, other customer fees and product returns.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Due to its limited history of product sales in the United States having only recently received regulatory approval for its first product, the Group has limited directly comparable information of actual rebate claims, chargebacks or levels of product returns, and the Group’s early sales information may have limited predictive value. The Group uses the expected value method to estimate revenue deductions, which considers the likelihood of a rebate, chargeback or product return being applicable to sales. The proportion of sales subject to a rebate or chargeback, and the level of product returns, is inherently uncertain and the Group’s estimates are based on internal assumptions, which may change as the Group develops more product experience, and third-party data, which the Group assesses for reliability and relevance.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Rebates and chargebacks</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">The Group is subject to state government Medicaid programs and other qualifying federal and state programs in the United States requiring rebates to be paid to participating state and local government entities, depending on the eligibility and circumstances of patients treated with KIMMTRAK after the Group has sold vials to specialty distributors. The Group is also subject to chargebacks from its specialty distributors under the 340B program in the United States, whereby qualifying hospitals are entitled to purchase KIMMTRAK at a lower price. For such sales, the Group’s specialty distributors charge back the difference between the wholesale acquisition cost and this lower price. Estimating rebate and chargeback deductions from revenue is judgmental due to the time delay between the date of the sale to specialty distributors and the subsequent dates on which the Group is able to determine actual amounts of chargebacks and rebates. The Group forms estimates of 340B chargeback deductions by</span> <span style="color: rgb(0, 0, 0);">analyzing sell-through data relating to the hospital mix of onward sales made by specialty distributors. For Medicaid and other rebates, </span>the Group forms estimates based on internal forecasts of the patient mix and external health coverage statistics<span style="color: rgb(0, 0, 0);">. Judgment is applied to consider the relevance and reliability of information used to make these estimates.</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Judgment is also required in determining the amount of the Group’s net pre-product revenue and product revenue in France. Rebates payable to the Economic Committee for Health Products (“CEPS”) under compassionate use, early access and commercial programs are subject to a high degree of estimation uncertainty. The Group’s estimate of these rebates represents the difference between the expected agreed price for the commercial sale of KIMMTRAK in France, which is subject to price negotiation, and the initial price of tebentafusp and KIMMTRAK sold under early access and commercial programs until this price is agreed. Analysis of further legislative requirements, sales volumes and the expected benefit of KIMMTRAK to patients in France is also required in the assessment of rebates payable. The Group applies judgement to assess internal targets, pricing information of other therapies approved for sale in France, information obtained from price negotiations of KIMMTRAK in other countries, and information connected with KIMMTRAK’s safety profile when forming its estimated rebate deduction from revenue.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Product returns</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Group considers several inputs when estimating potential levels of product returns. Due to the nature of KIMMTRAK as a therapy, the Group expects no product returns following patient administration by trained healthcare professionals. The Group applies judgement in assessing the level of returns for sales made to distributors which have yet to be administered to patients. The Group considers industry average return levels, distributor sell-through rates, the levels of inventory in the distribution channel, the period of time for which inventory has been held by its distributors, the level of orders placed, the expiry date of products sold, and its distributors’ right to return products in the case of vials of KIMMTRAK with a shorter period to expiry. As orders are typically placed based on scheduled administration by hospitals and healthcare facilities, the Group does not expect a significant level of product returns.</div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Significant Accounting Policies</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Product revenue, net</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Product revenue, net, relates to the sale of KIMMTRAK following marketing approval. The Group recognizes revenue at the point in time that control transfers to a customer, which is typically on delivery. The Group also operates under consignment arrangements where control passes when the Group’s distributor takes KIMMTRAK out of consignment inventory. The amount of revenue recognized under its arrangements reflects the consideration to which the Group expects to be entitled to, net of estimated deductions for rebates, chargebacks, other customer fees and product returns. Estimated revenue deductions are updated at the end of each reporting period using the latest available data. The Group considers whether any part of amounts expected to be received should be constrained to ensure that it is highly probable that a significant reversal in the cumulative revenue recognized will not occur. Estimating such deductions involves judgments which are detailed further above under “Critical accounting estimates”.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Group’s main customers in the United States and Europe are its distributors. These distributors are invoiced at contractual list prices with standard payment terms typically between <span style="-sec-ix-hidden:Fact_7deac9cd51f749f0b91f64d454f0639d">one</span> and two months. When the Group has the right to offset chargebacks against trade receivables and the parties have agreed to settle the payments net, chargebacks are recorded as a reduction in trade receivables. Other chargebacks, rebates and deductions are recognized as an accrual in the condensed consolidated statement of financial position.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; font-family: 'Times New Roman'; font-size: 10pt;">The Group’s customers are hospitals and healthcare providers in certain countries, where KIMMTRAK is sold through an agent acting on the Group’s behalf.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Pre-product revenue, net</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pre-product revenue, net, relates to the sale of tebentafusp under a compassionate use and an early access program in France up to September 2022. These programs provided patients with access to tebentafusp before KIMMTRAK became available as a marketed product in France. Pre-product revenue is recognized on delivery of tebentafusp to healthcare providers, which is the point in time when control is transferred. Such revenue is recognized net and represents the prices set by the Group that are expected to be retained after estimated deductions and to the extent that it is highly probable that a significant reversal of revenue will not occur. These variable estimated deductions include both an estimate of government rebates payable and an estimate of returns in the case of expiry, damage or other instances. The total rebate payable by the Group is dependent on the outcome of price negotiations with the French government, and the Group makes an estimate of these amounts payable each reporting period based on available pricing information and the applicable regulations. Returns are estimated based on industry trends and information provided by the Group’s distributors.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The estimates for rebates and returns deducted from pre-product revenue are recorded in the period the related pre-product revenue is recognized and are classified under Accruals within Trade and other payables in the Condensed Consolidated Statement of Financial Position. Costs of pre-product revenue are expensed when incurred and include costs associated with previous manufacturing of tebentafusp and other third-party selling expenses. Previous manufacturing costs were recognized in Research and development expenses at the time, and third-party selling expenses are recognized within Selling and administrative expenses.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenue</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenue represents production costs including raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale. Due to the Group’s manufacturing arrangements, overheads and internal costs of product revenue are minimal. Further information on Cost of product revenue is included within the ‘Inventories’ policy below.</div> P2M <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Trade Receivables</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Trade receivables include amounts invoiced or contractually accrued where only the passage of time is required before payment is received under the Group’s collaboration agreements and other revenue arrangements. Trade receivables are assessed for impairment using the simplified approach under IFRS 9, <span style="font-style: italic;">Financial Instruments</span>, which requires lifetime expected losses to be recognized with the initial recognition of the receivable. Due to its lack of sales history, the Group estimates expected credit losses using internal information, industry credit default information, and comparable information available from companies with similar customers. As of September 30, 2022, the amount of expected credit losses is not material.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Inventories</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Inventories include finished goods manufactured for commercial sale, items in the process of being manufactured for commercial sale, and the materials to be used in the manufacturing process. The principal costs in manufacturing the Group’s inventories are raw materials, external manufacturing costs, and other costs incurred in bringing inventories to their location and condition prior to sale.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Inventories are measured at weighted average cost and presented as assets in the Condensed Consolidated Statement of Financial Position to the extent that they are recoverable. Inventories are stated at the lower of cost and net realizable value, and the Group assesses whether an expense should be recognized to write down inventory values at each reporting period. Where this expense relates to inventories manufactured or developed following marketing approval of KIMMTRAK, the Group recognizes the expense within Cost of product revenue. Prior to receiving marketing approval, the Group recorded the expense for prelaunch inventory expected to be sold in the ordinary course of business within Research and development expenses. Reversals of previous write-downs of inventories are recognized within Cost of product revenue or Research and development expenses, depending on where the write-down was originally recognized.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As at September 30, 2022, the Group held a provision against the value of its inventories of £701,000, of which £185,000 has been recognized in Cost of product revenue in the Condensed Consolidated Statement of Profit / (Loss) and Comprehensive Loss in the nine months ended September 30, 2022.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Due to the low costs involved in manufacturing KIMMTRAK, inventory costs and Cost of product revenue are not material at this time, and the Group does not expect these costs to be material for the foreseeable future.</div>

701000

185000

<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">3. Revenue</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Revenue recognized during the three and nine months ended September 30, 2022 and 2021 consisted of Product revenue, net, from the sale of KIMMTRAK, Pre-product revenue, net, from the sale of tebentafusp under compassionate use and early access programs, and revenue from collaboration agreements.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Product revenue, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">33,252</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">64,926</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Pre-product revenue, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,051</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">9,588</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic;">Total revenue from sale of therapies</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">36,303</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">74,514</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic;">Collaboration revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">GSK</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,263</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5,919</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Eli Lilly</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">7,361</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Genentech</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">4,896</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">4,187</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,800</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,534</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic;">Total collaboration revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">4,896</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">5,450</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">21,161</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">19,453</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">41,199</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">5,924</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">95,675</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">19,927</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program are presented by region based on the location of the customer below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">United States</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">22,508</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">48,327</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Europe</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,034</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">25,423</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Rest of World</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">761</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">764</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Total revenue from sale of therapies</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">36,303</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">74,514</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Product revenue, net</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">During the three and nine months ended September 30, 2022, the Group recognized £33,252,000 and £64,926,000 of net product revenue, respectively, relating to the sale of KIMMTRAK primarily in the United States and Europe after estimated deductions for rebates, chargebacks, other customer fees and returns which are recognized in accruals as set out in the Group’s accounting policies.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Pre-product revenue, net</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">During the three and nine months ended September 30, 2022, the Group recognized £3,051,000 and £9,588,000 of net pre-product revenue, respectively, relating to the sale of tebentafusp under a compassionate use and early access program in France after estimated deductions for rebates and returns which are recognized in accruals as set out in the Group’s accounting policies (for both the three and nine months ended September 30, 2021: £474,000 of Pre-product revenue, net was recorded). In September 2022, the Group began selling KIMMTRAK as a commercial product in France, and these sales are reflected in Product revenue, net.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Genentech Collaboration</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">During the three and nine months ended September 30, 2022, the Group recognized £4,896,000 and £13,800,000 of revenue, respectively, relating to the 2018 Genentech Agreement and IMC-C103C (for the three and nine months ended September 30, 2021: £4,187,000 and £13,534,000, respectively). The revenue recognized represents both deductions from deferred revenue and research and development costs reimbursed, predominantly for clinical trial costs. Such reimbursements arise in order to ensure that research and development costs are shared equally under the 2018 Genentech Agreement. Of the revenue recognized during the three and nine months ended September 30, 2022, £624,000 and £984,000 of revenue represents research and development costs reimbursements. For the three and nine months ended September 30, 2021, the Group recognized research and development cost reimbursements of £87,000 and £717,000 respectively.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">GSK Collaboration</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">GSK and the Group elected not to progress the final program under the <span style="color: rgb(0, 0, 0);">GSK Agreement </span>in 2021, and there is no further revenue to recognize following notice of termination in 2021 and final termination of the GSK Agreement in the three months ended March 31, 2022. Accordingly, during the three and nine months ended September 30, 2022, the Group recognized no revenue relating to the GSK Agreement (for the three and nine months ended September 30, 2021: £1,263,000 and £5,919,000, respectively).</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Eli Lilly Collaboration</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">During the three and nine months ended September 30, 2022, the Group recognized £<span style="-sec-ix-hidden:Fact_c331b8f675534074a791095532ca04bb">nil</span> and £7,361,000, respectively, relating to the Eli Lilly Agreement (for the three and nine months ended September 30, 2021: £<span style="-sec-ix-hidden:Fact_dc58f0ed6a27440f8095e78ed88a2075"><span style="-sec-ix-hidden:Fact_89381e8d70ea47ec84677790cfce3175">nil</span></span>).</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; font-family: 'Times New Roman'; font-size: 10pt;">The Group released the remaining deferred revenue attributed to the third target under the collaboration after the parties agreed to terminate the agreement during the three months ended March 31, 2022. <span style="color: rgb(0, 0, 0);">No further revenue under the Eli Lilly Collaboration is expected.</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Deferred revenue</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Of the total revenue recognized during the three and nine months ended September 30, 2022, £4,272,000 and £20,177,000, respectively, was included in deferred revenue at January 1, 2022. No revenue was recognized in the three and nine months ended September 30, 2022 relating to performance obligations satisfied in previous years (for the three and nine months ended September 30, 2021: £<span style="-sec-ix-hidden:Fact_6e178892c63443f286ac0fd0bb2c0569"><span style="-sec-ix-hidden:Fact_658ef56e31f14ff691a2510a01987652">nil</span></span>). The remaining deferred revenue as at September 30, 2022 in the condensed consolidated statement of financial position relates to the 2018 Genentech agreement. The Group expects to recognize this remaining revenue within a year.</div>

<div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Revenue recognized during the three and nine months ended September 30, 2022 and 2021 consisted of Product revenue, net, from the sale of KIMMTRAK, Pre-product revenue, net, from the sale of tebentafusp under compassionate use and early access programs, and revenue from collaboration agreements.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Product revenue, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">33,252</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">64,926</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Pre-product revenue, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,051</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">9,588</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic;">Total revenue from sale of therapies</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">36,303</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">74,514</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic;">Collaboration revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">GSK</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,263</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5,919</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Eli Lilly</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">7,361</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Genentech</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">4,896</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">4,187</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,800</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,534</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic;">Total collaboration revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">4,896</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">5,450</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">21,161</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">19,453</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Total revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">41,199</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">5,924</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">95,675</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">19,927</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net product revenue from the sale of KIMMTRAK, and net pre-product revenue from the sale of tebentafusp as part of a compassionate use and early access program are presented by region based on the location of the customer below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">United States</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">22,508</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">48,327</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Europe</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">13,034</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">25,423</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Rest of World</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">761</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">764</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Total revenue from sale of therapies</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">36,303</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">74,514</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">474</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>

33252000 0 64926000 0 3051000 474000 9588000 474000

36303000

474000

74514000

474000

0 1263000 0 5919000 0 0 7361000 0 4896000 4187000 13800000 13534000 4896000 5450000 21161000 19453000

41199000

5924000

95675000

19927000

22508000

48327000

13034000

474000

25423000

474000

761000

764000

36303000

474000

74514000

474000

33252000 64926000 3051000 9588000 474000 474000 4896000 13800000 4187000 13534000

624000

984000

87000

717000

0 0 1263000 5919000 7361000

4272000 20177000 0 0 <div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">4. Selling and administrative expenses</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">There were £15,184,000 and £24,343,000, respectively, of foreign exchange gains, which the Group classifies within Selling and administrative expenses, for the three and nine months ended September 30, 2022, compared to gains of £3,338,000 and £1,080,000 in the three and nine months ended September 30, 2021. These gains arise on a number of foreign currency items, and the translation of monetary foreign currency balances in the Group’s main operating subsidiary in the United Kingdom has been significantly impacted by changes in exchange rates between pounds sterling and U.S. dollars in the three months ended September 30, 2022. The Group periodically assesses its exposure to foreign currency fluctuations </span>and, to the extent practical, seeks to minimize foreign currency risk by maintaining cash and cash equivalents of each currency at levels sufficient to meet foreseeable expenditure. The Group has not to date entered into hedging instruments to reduce the impact of foreign currency fluctuations, but it may do so in the future.</div>

15184000

24343000

3338000

1080000

<div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">5. Finance costs</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense on lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">461</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">428</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,316</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,301</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense on financial liabilities measured at amortized cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,324</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">889</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,199</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,164</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">1,785</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">1,317</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">4,515</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">4,465</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Interest expense on financial liabilities measured at amortized cost for the three and nine months ended September 30, 2022 and 2021 is related to the $50.0 million of borrowings under the Group’s debt facility with Oxford Finance. The expense for the nine months ended September 30, 2021, includes £546,000, representing a fee of $750,000, that became payable to Oxford Finance upon the completion of the IPO. The interest expense on the Group’s borrowings with Oxford Finance increased in the three months ended September 30, 2022, following an increase in the floating interest incurred on the loan. To reduce exposure to rising interest rates, the Group entered into a <span style="color: rgb(0, 0, 0);">loan agreement on November 8, 2022, with investment funds managed by Pharmakon Advisors, LP (the “<span style="color: rgb(0, 0, 0);">Pharmakon Loan Agreement”)</span>, providing for term loans to the Group in an aggregate principal amount of up to $100 million to be funded in two tranches. The first tranche, in the amount of $50 million, bears a fixed rate of interest of 9.75% and will mature in 6 years of draw. The proceeds from the first tranche, together with cash on hand, were used to repay the Group’s existing loan in the condensed consolidated statement of financial position of £45,563,000. This value at September 30, 2022 included a repayment fee of £1,579,000 (and excluded an early repayment fee of £225,000, which became payable when the Group elected to repay the Oxford loan).</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense on lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">461</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">428</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,316</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,301</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense on financial liabilities measured at amortized cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,324</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">889</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,199</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,164</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">1,785</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">1,317</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">4,515</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">4,465</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table>

461000

428000

1316000

1301000

1324000

889000

3199000

3164000

1785000

1317000

4515000

4465000

50000000

546000

750000

100000000 2 50000000

0.0975

P6Y

45563000

1579000

225000

<div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">6. Income tax</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">An income tax credit is recognized at an amount determined by multiplying the loss before taxation for the interim reporting period by the Group’s best estimate of the estimated annual income tax credit rate expected for the full financial year, adjusted for the tax effect of certain items recognized in full in the interim period. As such, the effective tax credit rate in the interim financial statements may differ from the Group’s estimate of the effective tax credit rate for the annual financial statements.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Group’s consolidated estimated effective tax credit rate for the nine months ended September 30, 2022 was 24.0% (for the nine months ended September 30, 2021: 9.5%). During the nine months ended September 30, 2022, the Company recorded a tax credit of £5,050,000 related to its research and development tax credits in the United Kingdom and the income tax obligations of its operating companies in the U.S. and the Republic of Ireland, which generate profit for tax purposes.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">A deferred tax asset of £3,860,000 has been recognized as of September 30, 2022 (December 31, 2021: £2,575,000) representing unused tax credits and capitalized research and development costs carried forward for one of the Group’s subsidiaries, Immunocore LLC, following a periodic assessment of all available and applicable information, including its forecasts of costs and future profitability and the resulting ability to utilise the recognized deferred tax assets over a short period of time.</div>

0.24 0.095

5050000

3860000

2575000

<div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">7. Basic and diluted profit / (loss) per share</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-weight: bold;"> 2022</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Profit / (loss) for the period (£’000s)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">6,228</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(30,134</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(16,021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(92,134</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Basic weighted average number of shares</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">46,998,420</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">43,796,084</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">44,944,827</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">42,030,746</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Adjustment for stock options with dilutive effect</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">4,444,856</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Diluted weighted average number of shares</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">51,443,276</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">43,796,084</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">44,944,827</div> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">42,030,746</div> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Basic earnings / (loss) per share (£) (1)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">0.13</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.36</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(2.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Diluted earnings / (loss) per share (£) (1)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">0.12</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.36</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(2.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(1) Basic profit / (loss) per share is calculated by dividing the profit or loss for the period attributable to the equity holders of the Group by the weighted average number of ordinary shares outstanding during the period, including ordinary shares represented by ADSs. Except for the three months ended September 30, 2022, the dilutive effect of potential shares through equity settled transactions is considered to be anti-dilutive as they would decrease the loss per share and are, therefore, excluded from the calculation of diluted loss per share. For the three months ended September 30, 2022, there were 88,695 of the potential ordinary shares granted under the Group’s option plans excluded from the calculation for diluted options per share, because they are considered to be anti-dilutive.</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-weight: bold;"> 2022</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Profit / (loss) for the period (£’000s)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">6,228</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(30,134</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(16,021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(92,134</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Basic weighted average number of shares</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">46,998,420</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">43,796,084</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">44,944,827</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">42,030,746</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Adjustment for stock options with dilutive effect</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">4,444,856</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Diluted weighted average number of shares</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">51,443,276</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">43,796,084</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">44,944,827</div> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">42,030,746</div> </td> <td colspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Basic earnings / (loss) per share (£) (1)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">0.13</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.36</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(2.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Diluted earnings / (loss) per share (£) (1)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">0.12</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(0.36</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">(2.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(1) Basic profit / (loss) per share is calculated by dividing the profit or loss for the period attributable to the equity holders of the Group by the weighted average number of ordinary shares outstanding during the period, including ordinary shares represented by ADSs. Except for the three months ended September 30, 2022, the dilutive effect of potential shares through equity settled transactions is considered to be anti-dilutive as they would decrease the loss per share and are, therefore, excluded from the calculation of diluted loss per share. For the three months ended September 30, 2022, there were 88,695 of the potential ordinary shares granted under the Group’s option plans excluded from the calculation for diluted options per share, because they are considered to be anti-dilutive.</div>

6228000

-30134000

-16021000

-92134000

46998420

43796084

44944827

42030746

4444856

51443276

43796084

44944827

42030746

0.13

-0.69

-0.36

-2.19

0.12

-0.69

-0.36

-2.19

88695

<div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">8. Trade and other receivables</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Trade receivables</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">25,809</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">6,047</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other receivables</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">6,214</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,470</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Prepayments and accrued income</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">8,945</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">7,691</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">40,968</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">15,208</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>

25809000

6047000

6214000

1470000

8945000

7691000

40968000

15208000

<div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">9. Leases</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="color: rgb(0, 0, 0);">On July 13, 2022, the Group entered into a new lease for additional laboratory space in the United Kingdom. The lease expires in 2042; however, it is freely terminable at the Group’s option at three points during the lease prior to the expiration date. The Group may be required to make total payments of up to £5,483,000 under the lease agreement</span>. The lease was previously disclosed as a contingent liability of £1,122,000 as at December 31, 2021, which represented the minimum amount of mandatory payments if the Group became required to enter into the lease.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">In the three months ended September 30, 2022, the Group recognized an initial right-of-use asset and lease liability of £2,472,000 in the Condensed Consolidated Statement of Financial Position in relation to this lease.</div>

5483000

1122000

2472000

<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">10. Capital and reserves</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In April 2022, the Company completed a reduction of its share capital, as contemplated in the registration statement for the Company’s initial public offering, whereby (i) the whole of the amount standing to the credit of the Company’s share premium account was cancelled and (ii) 23,702,856,974 ordinary shares and 457,338,326 non-voting ordinary shares (which were issued by way of a bonus issue on April 25, 2022 for the purpose of capitalising the Company’s merger reserve) were cancelled. The distributable reserves created by the reduction of capital amounted to £261.4 million.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In July 2022, the Company issued and sold 2,000,000 ADSs of nominal value £0.002 each and 1,733,333 non-voting ordinary shares of nominal value £0.002 each (the “PIPE Securities”), to certain institutional accredited investors (the “Investors”) at a purchase price of $37.50 per ordinary share as a private investment in public equity (“PIPE”) pursuant to a securities purchase agreement with such Investors dated July 15, 2022, generating gross proceeds of £116,812,000 ($140,000,000) before deducting offering expenses payable by the Company of £388,000.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; margin-right: 0.1pt; margin-left: 0.1pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Condensed Consolidated Statement of Changes in Equity shows the impact of the capital reduction and the PIPE. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The table below shows the movement in the number of issued shares during the nine months ended September 30, 2022.</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Ordinary Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Deferred Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">At January 1, 2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">43,862,850</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5,793,501</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">New shares issued for cash</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,733,333</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Exercise of share options</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">308,776</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">At September 30, 2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">47,904,959</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">5,793,501</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>

23702856974 457338326 261400000

2000000

0.002

1733333

0.002

37.5

116812000

140000000

388000

<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The table below shows the movement in the number of issued shares during the nine months ended September 30, 2022.</span> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Ordinary Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Deferred Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">At January 1, 2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">43,862,850</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">5,793,501</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">New shares issued for cash</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">3,733,333</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Exercise of share options</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">308,776</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">—</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">At September 30, 2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">47,904,959</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">5,793,501</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>

43862850

5793501

3733333

308776 0

47904959

5793501

<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">11. Share-based payments</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">During the three and nine months ended September 30, 2022 the total share-based payment charge was £6,093,000</span> and £20,181,000 respectively (for the three and nine months ended September 30, 2021, £9,200,000 and £27,138,000, respectively).</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company granted 2,100 and 4,000 options in the three months ended September 30, 2022, and 2021, respectively, and 1,365,753 and 4,538,527 options in the nine months ended September 30, 2022, and 2021, respectively. The options in both periods were valued using the Black-Scholes model, with the majority vesting over a four-year period from the date of grant, and with 25% of the award vesting at the end of the first year and the remaining award vesting quarterly over the following three years. In the nine months ended September 30, 2022, 66,972 options were awarded to the Company's non-executive directors, with the majority vesting after one year from the date of grant. </div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The weighted average fair value and exercise prices of options granted is set out below. </div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"> <span style="font-weight: bold;">2022<br/> </span></div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);"><br/> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">$ <br/> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; text-align: center;"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);"><br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">$ <br/> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; text-align: center; white-space: nowrap;"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">$ <br/> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; text-align: center; white-space: nowrap;"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">$ <br/> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Weighted average exercise price</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">37.25</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">39.02</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">25.49</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">26.19</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Weighted average fair value</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">23.58</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">23.69</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">15.63</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">16.28</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">A</span>s at September 30, 2022, and 2021, there were 9,942,203 and 9,199,742 outstanding options, respectively, of which 4,661,406 and 2,506,791 respectively, were exercisable.</div>

6093000

20181000

9200000

27138000

2100

4000

1365753

4538527

P4Y 0.25 P3Y

66972

P1Y

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The weighted average fair value and exercise prices of options granted is set out below. </div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the three months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> For the nine months ended</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);"> <span style="font-weight: bold;">2022<br/> </span></div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/> </div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);"><br/> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">$ <br/> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; text-align: center;"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);"><br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">$ <br/> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; text-align: center; white-space: nowrap;"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">$ <br/> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; text-align: center; white-space: nowrap;"> </td> <td colspan="1" style="text-align: center; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><br/> </td> <td colspan="1" style="vertical-align: bottom; text-align: center; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">$ <br/> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Weighted average exercise price</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">37.25</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">39.02</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">25.49</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">26.19</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Weighted average fair value</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">23.58</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">23.69</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">15.63</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">16.28</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> </table>

37.25

39.02

25.49

26.19

23.58 23.69 15.63 16.28

9942203

9199742

4661406

2506791

<div style="color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">12. Trade and other payables</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Trade payables</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">10,042</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">7,499</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other taxation and social security</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,423</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">532</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Accruals</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">53,078</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">27,382</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other payables</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">385</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">23</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">64,928</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">35,436</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Accruals include estimates for rebates, chargebacks, other customer fees and returns in respect of product revenue from the sale of KIMMTRAK and pre-product revenue from the sale of tebentafusp.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">September 30,</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div> <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">£’000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Trade payables</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">10,042</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">7,499</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other taxation and social security</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">1,423</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">532</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Accruals</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">53,078</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">27,382</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other payables</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">385</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0);">23</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">64,928</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="color: rgb(0, 0, 0); font-weight: bold;">35,436</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table>

10042000

7499000

1423000

532000

53078000

27382000

385000

23000

64928000

35436000

<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">13. Events after the reporting period</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On November 8, 2022, the Group entered into the Pharmakon Loan Agreement, providing for term loans to the Group in an aggregate principal amount of up to $100 million to be funded in two tranches. The first tranche, in the amount of $50 million, bears interest at a fixed rate of 9.75% and will mature in 6 years of draw. The Group used the proceeds from the first tranche, together with cash on hand, to repay in full the Group's existing $50 million loan from Oxford Finance and thereafter no further amounts may be borrowed pursuant to the loan agreement with Oxford Finance. The second tranche, consisting of one or two term loan(s) in an aggregate principal amount of up to $50 million (with a minimum draw of $25 million), is available until June 30, 2024 and may be advanced at the Group's election and, if and when drawn, is intended to be used to support the continued development and commercialization of the Company's pipeline and for other general purposes.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">On November 7, 2022, the Group and Medison Pharma Ltd (“Medison”) amended their exclusive distribution agreement from September 2021. Under the agreement, Medison will obtain all required marketing authorizations not currently obtained to date, market and distribute KIMMTRAK in Canada, Australia, New Zealand, Israel, Central and Eastern Europe, and, following the amendment, South and Central America, and the Caribbean. Under the distribution agreement, Medison is responsible for regulatory, sales and marketing, and distribution channel costs, and it receives a portion of net sales. Additionally, under the amended distribution agreement, Medison will pay the Group a non-refundable upfront fee of $5 million which the Group expects to receive in the three months ended December 31, 2022.</div>

100000000 2 50000000

0.0975

P6Y

50000000

1 2 50000000 25000000 5000000 Basic profit / (loss) per share is calculated by dividing the profit or loss for the period attributable to the equity holders of the Group by the weighted average number of ordinary shares outstanding during the period, including ordinary shares represented by ADSs. Except for the three months ended September 30, 2022, the dilutive effect of potential shares through equity settled transactions is considered to be anti-dilutive as they would decrease the loss per share and are, therefore, excluded from the calculation of diluted loss per share. For the three months ended September 30, 2022, there were 88,695 of the potential ordinary shares granted under the Group’s option plans excluded from the calculation for diluted options per share, because they are considered to be anti-dilutive. EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

'-D4$L! A0#% @ M(X)R56&UL4$L! A0#% @ (X)R5?MN3#77. 8<$# !4 M ( !A)